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1The work incorporated in the thesis with the title "STUDIES ON
COMPOUNDS OF THERAPEUTIC  INTEREST" has been described
as under :
[A] STUDIES ON PYRAZOLES
[B] STUDIES ON CHLORO QUINOLINES
[A] STUDIES ON PYRAZOLES
We are engaged in a programme to explore novel heterocyclic entities
in order to study their pharmacological profile. Our efforts are focused on
introduction of chemical diversity in the molecular frame work in order to
synthesizing active molecule of widely different composition.
Compounds bearing pyrazole moiety are endowed with a variety of
biological activities such as hypnotic, antitubercular, amoebicidal, herbicidal,
fungicidal, anticonvulsant, antiinflammatory, CNS depressant, antitumar and
plant growth regulatory activity etc.
Considering the increasing importance of pyrazole nucleus, the
synthesis of some novel chalcones, pyrazolines, thiazolidinopyrimidines,
acetonitriles and imidazolinones bearing 1-phenyl-3-p-methyl phenyl-
pyrazole nucleus has been undertaken.
PART - I : STUDIES ON CHALCONES
Chalcones are phenylstyryl ketones containing reactive ethylenic group
(-C-CH=CH-). Chalcone derivatives represents various biological activities
such as ant i thyroid,  ant i tubercular,  ant i fungal ,  ant imicrobial  and
antispasmodic activities. With a view to above findings, it appeared of interest
to synthesise chalcones with better potency as shown below.
O
SECTION - I : Synthesis and biological evaluation of 1-Aryl-3-
(1',N-phenyl-3'-p-tolyl-pyrazol-4'-yl)-2-propene-1-
ones
The chalcones of type (I) have been undertaken by the condensation
of 1-Phenyl-3-p-tolyl-4-formyl pyrazole with different aryl ketones in
presence of 40% NaOH.
PART - II : STUDIES ON PYRAZOLYLPYRAZOLINES
Among a wide variety of heterocycles that have been explored for
developing biologically active molecules like pyrazolines have played all
important role in medicinal chemistry. In present study, we report the synthesis,
antimicrobial, virucidal and initial pharmacological evaluation of new
pyrazoline derivatives bearing 1-phenyl-3-p-tolyl-4-formyl pyrazole moiety.
SECTION - I : Synthesis and biological evaluation of 3-Aryl-5-
[1',N-phenyl-3'-p-tolyl-pyrazol-4'-yl]-pyrazolines
The pyrazoline derivatives of type (II) have been prepared by the











Type - (II) R = Aryl
2
Type - (I) R = Aryl
SECTION - II : Synthesis and biological evaluation of 1,N-
Acetyl-3-aryl-5-[1',N-phenyl-3'-p-tolyl-pyrazol-4'-
yl]-pyrazolines
The pyrazolines derivatives of type (III) have been undertaken by the
reaction of compounds of type (I) with hydrazine hydrate in glacial acetic
acid.
SECTION - III : Synthesis and biological evaluation of 1,N-
Phenyl-3-aryl-5-[1',N-phenyl-3'-p-tolyl-pyrazol-4'-
yl]-pyrazolines
The pyrazolines of type (IV) have been prepared by the reaction of









Type - (III) R = Aryl







PART - III : STUDIES ON PYRIMIDINONES
Pyrimidinones possess remarkable pharmaceutical importance and
biological activity, some of the pyrimidinones, which occur as natural
products like nucelic acid and vitamin B, can be used as therapeutic agents,
for treatment of AIDS and antitumor agent keeping in association of
pyrimidinones with varied biological activity, it was thought worthwhile to
synthesis new pyrimidinones as under.
SECTION - I : Synthesis and biological evaluation of 2-
Arylimino-3,N-aryl-5-[1',N-phenyl-3'-p-tolyl-4'-
pyrazolylmethino]-4-thiazolidinones
The thiazolidinones of type (V) have been prepared by condensation









Type - (V) R = Aryl
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SECTION - II : Synthesis and biological evaluation of 6-
Arylimino-7,N-aryl-2-oxo-4-[1',N-phenyl-3'-p-
t o l y l - p y r a z o l - 4 ' - y l ] - 1 , 2 , 3 , 4 - t e t r a h y d r o -
thiazolidino-[4,5-d]-pyrimidines
The compounds of type (VI) have been synthesized by the condensation
of compounds of type (V) with urea, in presence of HCl as catalyst.
PART - IV : STUDIES ON THIOPYRIMIDINES
Thiopyrimidines represent one of the most active classes of compounds
possessing wide spectrum of biological activities, such as significant in vitro
activity against DNA and RNA viruses including polio and Herper viruses,
diuretic, antitubercular, etc. In view of these facts, it was contemplated to













Type - (VI) R = Aryl
5
SECTION - I : Synthesis and biological evaluation of 6-
Arylimino-7,N-aryl-2-thio-4-[1',N-phenyl-3'-p-
t o l y l - p y r a z o l - 4 ' - y l ] - 1 , 2 , 3 , 4 - t e t r a h y d r o -
thiazolidino-[4,5-d]-pyrimidines
The compounds of type (VII) have been synthesized by the condensation
of compounds of type (V) with thiourea in presence of HCl as catalyst.
PART - V : STUDIES ON AMINOPYRIMIDINES
It has been reported that pyrimidine derivatives are associated with
various biological activities like antifungal, antitubercular, antibacterial,
herbicidal etc. These valid observations contemplated us to synthesise amino
pyrimidine derivatives which have been described as under.



























R = ArylType - (VIII)
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The compounds of  type (VII I )  have been synthesized by the
condensation of compounds of type (V) with guanidine hydrochloride in
presence of HCl as catalyst.
PART - VI : STUDIES ON NITRILES
Recently substituted nitriles have drawn considerable attention due to
their good pharmacological activities like cardiovascular, sedative, antifungal
and antibacterial. By considering these valid observations, we have
synthesised some new nitriles which have been described as under.
SECTION - I : Synthesis and biological evaluation of α -
Arylamino-1,N-phenyl-3-p-tolyl-pyrazol-4-yl-
acetonitriles
The nitriles of type (IX) have been prepared by the condensation of
1-N-Phenyl-3-p-tolyl-4-formyl pyrazole with different aromatic amines by
the presence of potassium cyanide and glacial acetic acid at 0-5oC.
PART - VII : STUDIES ON IMIDAZOLINONES
Imidazolinones have been found to be potent drug in pharmaceutical
and possess a wide range of biological activities such as anticonvulsant,
sedative, hypnotic, antiinflammatory, antihistamine and antithyroid. In order
to develop medicinally important compounds, we have synthesised some






Type - (IX) R = Aryl
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SECTION - I : Synthesis and biological evaluation of 1,N-Aryl-
2 - a l k y l / a r y l - 4 - [ 1 ' ,N -pheny l - 3 ' - p - t o l y l - 4 ' -
pyrazolylmethine]-imidazolin-5-ones
The imidazolinone derivatives of type (X) have been prepared by the
reaction of azalactone with different aryl amines in pyridine.
[B] STUDIES ON CHLOROQUINOLINES
Nitrogen containing heterocyclic compounds like quinoline have
received considerable attention in recent years due to their biological and
pharmaceutical activities like anticonvulsant, sedative, tuberculosatatic,
antihypertensive, hypnotics, antimalarial, antibacterial, antifungal, and many
others. Considering the increasing importance of quinoline nucleus, the
synthesis of some novel chalcones, cyanopyridines and azomethines bearing
2-Chloro-6-methoxy-3-quinolin-carboxaldehyde moiety has been under
taken.
PART - VIII : STUDIES ON CYANOPYRIDINES
Cyanopyridines have been reported to be active as antibacterial,
antifungal, antidiabetic, anticholestermic and antihypertensive agent. They
have been also used as dyes for cotton and polyester fabrics. These findings
prompted us to synthesise some representative cyanopyridines possessing











R2 = Alkyl/ Aryl
SECTION - I : Synthesis and biological evaluation of 1-Aryl-3-
[2'-chloro-6'-methoxy-quinolin-3'-yl]-2-propene-
1-ones
The chalcones of type (XI) have been synthesised by the condensation
of 2-Chloro-6-methoxy-3-quinolincarboxaldehyde with various aromatic
ketones.
SECTION - II : Synthesis and biological evaluation of 2-Amino-
3-cyano-4-[2'-chloro-6'-methoxy quinolin-3'-yl]-
6-aryl-pyridines
2-Amino cyanopyridines of type (XII) have been prepared by the
condensation of chalcones of type (XI) with ammonium acetate and
malononitrile.















PART - IX : STUDIES ON AZOMETHINE DERIVATIVES
Azomethine derivatives represents one of the modest classes of
compounds possessing wide range of therapeutic activities, such as
antimicrobial, antimalerial, antibacterial. With a view to getting better
therapeutic agents and to evaluate it's pharmacological profile, different type
of azomethine derivatives have been prepared, which have been described
as under.
SECTION - I : Synthesis and biological evaluation of N-Aryl-
2-chloro-6-methoxy-quinolin-3-yl-azomethines
The azomethines of type (XIII) have been prepared by the condensation
of 2-Chloro-6-methoxy-3-quinolincarboxaldehyde with different aromatic
amines.
SECTION - II : Synthesis and biological evaluation of 2-Chloro-
6-methoxy-3-arylaminomethyl quinolines
The compounds of type (XIV) have been prepared by the reaction of
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PART - X : STUDIES ON NITRILES
Recently substituted nitrile derivatives have drawn considerable
attention due to their good pharmacological activities. By considering these
valid observations, we have synthesised some new nitriles which have been
described as under.
SECTION - I : Synthesis and biological evaluation of α -
Arylamino-[2-chloro-6-methoxy-quinolin-3-yl]-
acetonitriles
The nitriles of type (XV) have been prepared by the condensation of
2-Chloro-6-methoxy-3-quinolincarboxaldehyde cyanohydrine with different
aromatic amines.
The constitution of the synthesized product have been characterised
by using elemental analysis, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. Purity of all the
compounds have been checked by thin layer chromatography.
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In vitro study on multiple biological activities.
(1) All the compounds have been evaluated for their in vitro biological
assay like antitubercular activity towards a strain of  Mycobacterium
tuberculosis H37 Rv at a concentration of 6.25 µg/ml using Rifampin
as standard drug, which have been tested by Tuberculosis Antimicrobial
Acquistion Coordination Facility (TAACF), Alabama, U.S.A.
(2) All the compounds have been also evaluted for their antibacterial
activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at concentration of
40 µg/ml. The biological activity of the synthesized compounds have








The current interest in the creation of large, searchable libraries of organic
compounds have captured an imagination of chemists and the drug discovery
community. Ettorts in numerous laboratories focused on the introduction of
chemical diversity have been recently reviewed and pharmacologically interesting
compounds have been identified from libraries of widely different compositions.
The progress of drug design is extensively driven by the instincts, intution
and experience of pharmaceutical research scientists. It is often instructive to
attempt to 'capture' these experiences by analysing the historical record that is
successful drug design projects to past. From this anlysis the interference draw to
play an important role in shaping our on current and future projects. Towards
this region, we would like to analyse the structures of a large number of drugs.
The ultimate product of a successful drug design ettort. Our goal for this is
to begin to deconvolute this information in order to apply it to design of new
drugs.
Many natural products by trial and error, come into practice for combating
human ailments existent during early human observation. With the advent of
modern scientific approach, various plant medicines come under chemical
scrutiny, ultimately leading to the isolation of active principles since early.
Such compounds either in extract form or in pure form bacame part of
pharmacopoeisu. For intanse, though the chinese drug, Mauhany was in use for
over 5000 years for the treatment of various types of fever and respiratory ailments,
its active principle ephidrine was isolated in 1887. In 1925 chemical investigations
13
followed by pharmacological evaluation led this compound into the modern
medicine. Similarly during this period, urea stibamine was introduced as the first
drug in 1920 for the treatment of Kala azar, in 1930 De Raywolfia preparation
were first employed for sedative and hypotensive properties.
A drug is a substances having abnormal effect on certain body functions
estrichnine stimulates the action of heart and aspirin still it action since both of
them effects abnormally the two substances are known as drugs chemical sciences
contributed extensively new discoveries leading to useful drug after 1930.
The modern concept of drug discovery supported in 1933 by Gerhand
Domayk with his finding of "Prontosil Red" a compound responsible for the
antibacterial activity. The advert of sulphonamides draw attention to the different
acitvity of various chemicals for bacterial and human cells, this important factor
prompted the Florey and chain in 1939 to investigate penicillins which was
discovered ten years earlier by Aexander Fleming.
A large number of important drugs have been introduced during the period
of 1940 to 1960. This perod is knowns as 'Golden Period' ot new drug discovery.
Thus starting from 1933 - the first antibacterial drug prontosil leading various
sulpha drugs; 1940-penicillin; 1945-chloroquine; an antimalarial ; 1950-
methyldopa-antidiabetic; 1957-chlorothiaido-diuretic; 1958-adrenergic beta
blockers coronary vasodilatory; 1960 - semi synthetic penicillin, antibacterial;
1965-trimethoprim-antimicrobial; 1967-disodium chromoglycate, antiallergic;
1972-cimetidine, H2-antagonist; 1975-verapamil, calcium antagonist; 1981-
captopril antihypertensive. There are some specific examples representing new
therapeutics.
The spectacular chemotherapeutical properties of penicillin and its dramatic
time was development for the treatment of wound made penicillin, a most
commonly used inexpensive drug.
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Taking in view of the applicability of heterocyclic compounds, we have
undertaken the preparation of heterocycles bearing pyrazole nucleus. The
placement of a wide variety of substituents of these nuclei have been designed
in order to evaluate the synthesised products for their pharmacological profile
against several strains of bacteria and fungi.
AIMS AND OBJECTIVES :
v To generate several  der ivat ives l ike ary ledenes,  th iopyr imidines,
oxopyrimidenes, aminopyrimidines, chalcones, pyrazolines, imidazolines,
nitriles bearing pyrazole moiety.
v To synthesise therapeutically active moieties like chalcones, cyanopyridines,
nitriles, azomethines bearing chloro quinoline moiety.
v To characterise these products for structure elucidation using spectroscopic
technique like IR, PMR and Mass spectral studies.
v Purity of all compounds have been checked by thin layer chromatography.
v To evaluate these new product for better drug potential against different
strain of bacteria, fungi and for antitubercular activity.
The research work is presentated as studies on [A] pyrazoles and [B]
chloroquinolines.
Studies on pyrazoles includes seven parts and studies on chloroquinolines.






The pyrazole ring system (1) consists of a doubly unsaturated five membered
ring containing two adjacent carbon atoms. Knorr1,2 first synthesised a compound
containing this system in 1883 by a reaction of ethylacetoacetate with
phenylhydrazine which 1-Phenyl-3-methyl-5-pyrazolene (II).
Knorr3 introduced the name pyrazole for these compounds to donate that
the nucleus was derived from pyrrole by replacement of carbon by nitrogen ;
Since many drugs and dyes contain the pyrazole nucleus, the class has been
widely studied and the field continuous to be active today even though antipyrine
and related medicine no longer in common use. Pyrazolone dyes are especially
important in colour photography.
SYNTHETIC ASPECT :
Various methods for the preparation of pyrazoles have been cited in literature.
1. The reation of hydrazine or it's derivatives such as alkyl or aryl hydrazines,
















2. The reaction of hydrazines with α,β-unsaturated carbonyl compounds.
3. The reaction of aliphatic diazo compounds such as diazomethane or
diazoester with acetylene or olefins.
THERAPEUTIC IMPORTANCE
Much research has been carried out with the aim to finding therapeutic
values of pyrazole moiety since their discovery. A large number of substituted








8. P-38 Kinase inhibitors15-18
9. Antiepileptic19
10. Nemeticidal20
Feid-Allah Hassan21 have prepared pyrazoles and reported their antidiabetic
and antibacterial activity. Ejima Akio et al.22 have synthesised pyrazole
derivatives as antitumor agents (III).













Havaldar Freddy et al.24 synthesised 4,5-dihydro 3-phenyl-1H-pyrazole and
reported their bialogical activity. Carbau Romuald and co-worker25 have
prepared pyrazole derivatives (V) useful as reverse transcriptase inhibitors for
the treatment of HIV infection.
Jansen Karte et al.26 have synthesised pyrazole derivatives as pesticides.
Somega Shinzo and co-workers27 have synthesised pyrazole derivatives and
reported their herbicidal activity. Geheing Reinhald et al.28 have synthesised 5-
Amino-4-cyano-1-aryl-pyrazoles and shown them as plant growth inhibitors.
Nakamura Katsyga and co-worker29,30 have prepared 1,5-diphenyl pyrazoles
as Cox-2-inhibitors (VI).
Pier Giovanni Baraldi et al.31 synthesised pyrazole derivatives as
antileukemic agents. Thomas Alan Crowell et al.32 prepared new pyrazoles as
selective β3 adernergic agonists. Kevin M. Moore et al.
33 prepared pyrazoles as
human dopamine-D4-receptors. Bernard Banks et al.
34 have synthesised






























Grazid Mamalo et al.35 have newly synthsised pyrazole derivaties tested for
antimicrobial activity. R. Y. Huang and co-worker36 have prepared some 1,2,4-
triaryl-4-alkyl-pyrazoles as estrogen receptor. C. Vittoria and co-worker37 have
prepared some pyrazoles as adinosine receptor antagonists.
Laborde Edgardo et al.38 have found that pyrazoles possess glycine
transporter-2-inhibitor activity. Andrew Thurkaub et al.39 have synthesised
high affinity C5a receptor modulator pyrazoles. Nagaaki Sato et al.
40 have
prepared pyrazoles as neuropeptide T5 receptor antagonist. G.M.B. Hi
Yamanonch pharma. co41 has prepared pyrazoles as glycine transporter
protein inhibitors.
Recently, Atkinson R. N. et al.42 have synthesised pyrazoles as sodium
channel Blocker (VIII). Murakanii Hiroshi et al.43 have synthesised pyrazoles as
antifouling agent. Gelliber t Francoise et al.44 have synthesised pyrazole
derivatives as TGF-13 inhibitors.
Jacques Dumas and co-worker45 have prepared pyrazole derivatives as
rafkinase and angiogenesis inhibitor agents. David L. S. et al.46 have synthesised
pyrazoles as activators of the nitrile oxide receptor and soluble guanglate cyclase
agent. T Van Herk et al.47 have synthesised pyrazoles as nicotinic acid receptor















Nishimura Tsoshihiro et al.49 have synthesised pyrazoles as inhibitors of
human SGLT2 (sodium dependent glucose transporter-2). Recently it is found
that pyrazole derivatives possesses a number of biological activities. Such as
fungicidal50,51, herbicidal52-55, cardiovascular51, antiinflammatory57-59,
Cox-II inhibitor60, antimicrobial61, anticancer62-64, protein kinase inhibitor65-
68, antibacterial69,70, antiviral71, antiparasitic72, HIV reverse transcriptase
inhibitor73,74, and 5-H T2O receptors.
75-77
Literature survey reveals that the compounds bearing pyrazole moiety in
general passage potential drug activity. Looking to the diversified biological
activity, it appeared of interest to synthesise some chalcones, pyrazolines,
pyrimidinones, thiopyrimidines, aminopyrimidines, nitriles, imidazolinones and
thiaozolidinones bearing pyrazole moiety, in order to achieving compounds having
better therapeutic importance. These studies are described in following parts.
[A] STUDIES ON PYRAZOLES
PART-I : STUDIES ON CHALCONES
PART- II : STUDIES ON PYRAZOLYLPYRAZOLINES
PART- III: STUDIES ON PYRIMIDINONES
PART-IV : STUDIES ON THIOPYRIMIDINES
PART-V : STUDIES ON AMINOPYRIMIDINES
PART-VI : STUDIES ON NITRILES






The chemistry of chalcones have generated intensive scientific studies
throughout the world, specially interesting are their biological and industrial
applications. Chalcones are coloured compounds because of the presence of the
chromophore and auxochromes. They are known as benzalacetophenones or
benzyl idene acetophenones. Kostanecki and Tambor78 gave the name
"Chalcone"
Chalcones are characterised by their possession of a structure in which two
aromatic rings A and B are linked by an aliphatic three carbon chain.
The alternative names given to chalcones are phenyl stryl ketones,
beanzalacetophenone, β-phenyl acrylphenone, γ-oxo-α,γ-diphenyl-α-propylene
and α-phenyl-β-benzoethylene.
SYNTHETIC ASPECT :
A considerable variety of methods are available for the synthesis of
chalcones. The most convenient method is the one that involves the claisen-
schimdt condensation of equimolar quantities of an aryl methyl ketones with
arylaldehyde in presence of alcoholic alkali79.
Several condensing agents used are alkali of different strength80,81
hydrogen chloride82,83, phosphorous oxychloride84, piperidine85, anhydrous
aluminium chloride86, boron trifluoride87, aq. solution of borax88, amino






Chalcone formation proceeds through Aldal type of condensation and the
process is catalysed by the presence of alkali.91 Following are the steps of the
reaction mechanism.
The intermediate Aldol type of products formed readily undergoes
dehydration even under mild condition, perticularly when R and R1 are aryl
groups.
REACTIVITY OF CHALCONES :
The chalcones have been found to be useful for the synthesis of variety of
heterocyclic compounds are as under.
(a) Pyrazolines92 and its derivatives can be prepared by the condensation of
chalcones with hydrazine hydrate and acetic acid.
(b) Chalcones on condensation with malononitrile and ammonium acetate
yields 2-amino-3-cyano pyridines.93
(c) Isoxazoles94 can be prepared by the treatment of chalcones with
hydroxylamine hydrochloride and sodium acetate.
(i) CH
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(d) Chalcones on condensation with malononitrile in pyridine forms 2-amino-
3-cyano-pyrans.95
(e) Chalcones on treatment with urea in presence of alkali affords 2-oxo-
pyrimidines.96
(f) Chalcones on reaction with thiourea in presence of alkali/acid yields 2-
thienopyrimidines.97
(g) Chalcones on treatment with guanidine hydrochloride in presence of alkali
affords 2-amino pyrimidines.98
(h) Chalcones reacts with P2S5 yielding 2-isothiazolidines.
99
(i) Chalcones reacts with sodium nitrile in presence of glacial acetic acid in
ethanol produces 2-1H-pyrimidines.100
(j) Chalcones with monoethanolamine in ethanol gives 1,4-oxazipines.101
(k) Chalcones wi th 2-amino thiophenal  in acet ic  acid produces 1,5-
thiazepines.102
(l) Chalcones on reaction with semicarbazide hydrochloride in ethanol affords
1-carboxamide pyrazolines.103
(m) Chalcones on reaction with 2-aminopyridine in glacial acetic acid affords
pyridopyrimidines.104
(n) Oxiran105 can be prepared by the reaction of chalcone with H2O2 in basic
media.
(o) Cyanopyridone106 derivatives can be prepared by the condensation of
chalcone with ethyl cyanoacetate.
(p) Chalcones on reaction with barbituric acid gave barbitone107 derivatives.
(q) Chalcone gives imine derivatives with amine in presence of sulfuric acid as
catalyst.108
THERAPEUTIC INTEREST :
Chalcones are potential biocides, some naturally occuring antibiotics and
















Moreover, synthesis and antibacterial activity of substituted chalcone
derivatives have been reported by Modi et al.127 and Attia A.128 V. Mudalir et
al.129 have prepared phenoxychalcones and observed their insecticidal activity,
Kammei et al.130 have synthesised  chalone derivatives having antitumor activity.
De Vincenzo et al.131 and Han et al.132 have reported chalcone derivatives for
their antiinflammatory activity.
Aldose reductase inhibitor activity of chalcone derivatives have been
reported by Okuyama et al.133 They are also associated with antitumor and
antifungal activity as reported by Tsotitns and co-worker134 Antifeedant activity
of chalcones have been observed by Sarma and Sreenivasulu.135
Ezico et al.136 have demonstrated that chalcone possess a valuable
antiproliferation activity both on sensitive cancereous cell and on cell which are
resistant to common chemotherapeutic drugs. Some of the chalcones have been
patented for their use for treatment of glueoma137 and showed antifungal138,139
aldose reductase inhibitors140, anticancer141 and antimicrobial142,143
activities.
24Chalcones...
Recently Ni Liming et al.144 have synthesised chalcones and screened for
their antiinflammatory and cardiovascular activity Kumar Srinivas et al.145 have
synthesised chalcones as a antitumor agent. Ko Horng-Huey et al.146 have
prepared chalcones as antiinflammatory agent. Nakahara Kazuhiko et al.147 have
synthesised chalcones as carcinogen inhibitors. Antitubercular agents of chalcone
derivatives have been prepared by Lin Yuh-Meei et al.148
Das B. P. et al.149 have found that chalcones possesses larvicidal properties.
Kim Min-Young et al.150 have synthesised chalcones and tested for their matrix
metalloproteinase inhibitor activity. Liu Mei et al.151 have prepared antimalarial
chalcones. Opletalova Veronika et al.152 have synthesised chalcones and
screened as cardiovascular agents.
Moreover, it has been found that chalcone derivatives possesses nitric oxide
inhibitor (II), 153,154 anti HIV155,156 and antiproliferative157,158 (III)
activities.
Chalcone bearing a very good synthon variety of novel heterocycles with
good pharmacological profile can be designed. These valid observation led us
to explore chalcone chemistry by synthesising several derivatives like pyrazolines,
arylidenes, pyrimidinones, thiopyrimidines, thiazolidinones and imidazolines
bearing different heterocylic ring systems for medicinal value, in order to
achieving better therapeutic agents, this study described as under.













R1-R7  = H, OH, OMe
SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-ARYL-3-[1'-N-
PHENYL-3'-p-TOLYL-PYRAZOL-4'-YL]-2-PROPENE-1-ONES
Recently much interest has been focused on the synthesis and biodynamic
activities of chalcones and it is a good synthon for verious heterocyclic rings,
with a view to obtained compounds having better therapeutic activity, we have
synthesised 1-Aryl-3-(1',N-phenyl-3-p-tolyl-pyrazol-4'-yl)-2-propene-1-ones by
the condensation of 1,N-Phenyl-3-p-tolyl-4-formyl-pyrazole with various aromatic
ketones.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. when R=4-methoxyphenyl molecular
weight=394, m/z=395 (m+1)
All the compounds have been also evaluated for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40 µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs. Some
compounds have been found to have good and equivalent activity as compared
to the known anibiotics recorded on Page No38. The details have been cited in
part-I, Section-I(D).










































Type - (I) R = Aryl
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IR SPECTRAL STUDY OF 1-p-CHLOROPHENYL-3-(1',N-PHENYL-3'-p-TOLYL-PYRAZOL-
4'-YL)-2-PROPENE-1-ONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2920 2975-2950 614
-CH3 C – H str.(sym.) 2856 2880-2860 "
C= H s.p. (def.) 1450 1470-1435 "
C-H o.o.p. (def.) 1406 1395-1370 "
Aromatic C – H str. 3060 3090-3030 615
C = C str. 1535 1585-1570 "
1502 1520-1480 "
C – H.i.p. (def.) 1089 1125-1090 "
1060 1070-1000 "
C–H. o.o.p. (def.) 823 835-810 "
Pyrazole C = N str 1593 1610-1590 616
moiety C – N str. 1213 1230-1020 "
α−β-unsaturated – C= O str. 1658 1700-1640 617
ketone – CH=CH–str. 1502 1644-1618 "
C–H wag. 981 980-965 618






PMR SPECTRAL STADY OF  1-p-ANISYL-3-(1',N-PHENYL-3'-p-TOLYL-PYRAZOL-4'-YL)-
2-PROPENE-1-ONE
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 2.42 3H singlet Ar-CH3 -
2. 3.86 3H singlet Ar-OCH3 -
3. 6.93-6.96 2H doublet Ar-H g,g' Jgf=8.8
4. 7.25-7.35 3H multiplet Ar-H (a,c,e) -
5. 7.45-7.50 2H triplet Ar-H (b,d) -
6. 7.58-7.61 2H doublet Ar-H f,f' Jfg=8.8
7. 7.77-7.80 2H doublet Ar-H i,i' Jij=8.2
8. 7.84-7.89 2H doublet -CH (k&l) Jkl&lk = 15.6
9. 7.94-7.98 2H doublet Ar-H j j' Jji=8.2







































































































































Gran positive bacterial : Staphylococcus aureus
Bacillus Megaterium
Gram negative bacterial : Proteus Vulgaris
Escherichia Coli
Fungi : Aspergillus niger
Concentration : 40 µg.
Solvent : Dimethyl formamide
Standard drug : Ampicillin, Amoxicillin, Norfloxacin,
Penicillin, Creseofulvin
The antimicrobial activity was compared with standard drug viz. Ampicillin,
Amoxicillin, Norfloxacin, Penicillin and antifungal activity was compared with
viz Greseofulvin. The inhibition zones measured in mm.
ANTITUBERCULAR ACTIVITY
The antitubercular activity was curried out at Tubrerculosis Antimicrobial
Acquisition and co-ordinating Facility (TAACF) U.S.A.
Method : BACTEC 460 Radiometric system.
Bacteria : Mycobacterium tuberculosis H37Rv
Cuncentrtion : 6.25 µg/ml.
Standard drug : Rifampin
32
EXPERIMENTAL
SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-ARYL-3-(1',N-
PHENYL-3'-P-TOLYL-PYRAZOL-4'-YL)-2-PROPENE-1-ONES
[A] Synthesis of N-Phenylamine-α-methyl-α-p-tolyl azomethine
A mixture of Phenylhydrazine (1.08 gm, 0.01m) and 4-methyl acetophenone
(1.34gm, 0.01m) in absolute ethanol was refluxed in waterbath for 4 hrs. in
presence of 1ml glacial acetic acid. Product obtained after cooling was crystalized
from absolute ethanol. Yield, 78% (1.74gm); m.p. 62oC; (C15H16N2 ;Found: C,
80.32%; H,7.19%; N,12.49%; Required : C, 80.28%; H, 7.14%; N,12.43%).
TLC solvent system : Acetone : Benzene (0.5 : 9.5).
[B] Synthesis of 1,N-Phenyl-3-p-tolyl-4-formyl pyrazole
A compound N-PhenylaAmine-α-methyl-α-p-tolyl-azomethine (0.89 gm,
0.004M) was added in a mixture et Vilsmeier-Haack reagent (prepared by
dropwise addition of 1.2ml POCl3 in ice cooled 10ml DMF) and refluxed for 6
hrs. The reaction mixture was poured into crushed ice followed by neutralization
using sodium bicarbonate. Crude product was isolated and crystallized from
methanol. Yield, 83%; m.p. 114oC ; (C
17
H14N2O ; Found: C,77.84%; H,5.38%;
N,10.68% Required : C,72.82% ; H,5.34%; N,10.63%).
TLC solvent system : Acetone : Benzene (1:9).
[C] Synthesis of 1-(p-Anisyl)-3-(1'-N-phenyl-3'-p-tolyl-pyrazol-4'-yl)-2-
propene-1-one
To a well stirred solution of 1,N-Phenyl-3-p-toly-4-formyl-pyrazole (2.62gm,
0.01M) and p-methoxy-acetophenone (1.5gm, 0.01M) in ethanol (25 ml), 40%
NaOH added till the solution become basic. The reaction mixture was stirred
for 24 hrs. The contents were poured into ice, acidified, filtered and crystallized
from ethanol. Yield,77% (3.0 gm); m.p.116oC. (C26H22N2O2 ; Found :
C,79.16%; H,5.62% ; N,7.10% ; Required : C,79.13%; H, 5.58%; N, 7.03%).
TLC solvent system : Acetone : Benzene (2:8).
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 Similarly other substituted chalcones have been prepared. The physical
data are recorded in Table No. I.
[D] Antimicrobial and antitubercular activity of 1-Ary-3-(1',N-phenyl-
3'-p-tolyl-pyrazol-4'-yl)-2-propene-1-ones
All the compounds have been evaluated for antimicrobial and antitubercular
activity as described under.
(a) Antimicrobial activity
It was carried out buy cup-plate diffusion method which has been described
as under.
(I) Antibacterial activity
The purified products were screened for their antimicrobial activity. The
nutrient agar bath propared by the usual method, was inoculated aseptically with
0.5 ml of 24 hrs. old subcultures of B. mega, S. aureus, E. Coli, P. vulgaris
in separate conical flasks at 40-50oC and mixed well by gentle shaking. About
25ml content of the flask were poured and evenly spreaded in a petridish (13 cm
in diameter) and allowed to set for 2 hrs. The cups (10 mm in diameter) were
formed by the help of borar in agar medium and filled with 0.04ml (40 µg) solution
of sample in DMF.
The plates were incubated at 37oC for 24 hrs. and the control was also
maintained with 0.04 mole of DMF in a similar manner and the zones of inhibition
of bacterial growth were measured in millimeter and are recorded in Graphical
Chart No.1.
(II) Antifungal activity
A. niger was employed for testing antifungal activity using cup-plate method.
The culture was maintained on subouraud's agar slants. Sterllised sabouraud's
agar medium was inoculated with 72 hrs. old 0.5 ml suspension of fungal spores
34
in a separate flask.
About 25 ml of inoculated medium was evenly spreaded in a petridish and
allowed to set for two hrs. The plates were incubated at 30oC for 48 hrs. After the
completion of incubation period, the zone of inhibition of growth in the form of
diameter in mm was measured. Along the test solution in each petridish one cup
was fillled with solvent which act as control. The zones of inhibition are recorded
in Graphical Chart No. 1.
(b) Antituberculer activity
The antitubercular  evaluation of compounds were carried out at tuberculosis
Antimicrobial Acquisition co-ordinating Facillity (TAACF), U.S.A. Primary
screening of the compounds for antitubercular activity have been conducted at
6.25 µg/ml towards mycobacterium tuberculosis H37 Rv in BACTEC 12B
medium using the BACTEC 460 radiometr ic  sys tem. The compounds
demonstrating atleast > 90% inhibition in the primary screen have been retested
at lower concentration towards mycobacterium tuberculosis H37Rv to
determine the actual minimum inhibitory concentration (MIC) in the BACTEC
460.
The antitubercular activity data have been compared with standard drug,























1a C6H5- C25H20N2O 364 186 0.535 63 7.69 7.63
1b 4-Br-C6H4- C25H19N2OBr 443 130 0.657 56 6.32 6.37
1c 4-Cl-C6H4- C25H19N2OCl 398.5 148 0.552 60 7.02 7.08
1d 4-F-C6H4- C25H19N2OF 382 226 0.488 70 7.33 7.26
1e 4-CH3-C6H4- C26H22N2O 378 190 0.511 72 7.40 7.33
1f 4-OCH3-C6H4- C26H22N2O2 394 116 0.588 77 7.10 7.03
1g 2-OH-C6H4- C25H20N2O2 380 160 0.544 66 7.36 7.33
1h 4-OH-C6H4- C25H20N2O2 380 144 0.591 69 7.36 7.38
1i 4-NH2-C6H4- C25H21N3O 379 180 0.477 57 11.07 11.02
1j 3-NO2-C6H4- C25H19N3O3 409 167 0.576 58 10.26 10.18
1k 4-NO2-C6H4- C25H19N3O3 409 195 0.490 59 10.26 10.29
1l 2-C4H3S- C23H18N2OS 370 160 0.457 60 7.56 7.51

































B.mega 13 15 18 14 16 17 18 19 21 20 16 18 23 22 24
S.aureus 15 13 14 12 14 14 13 18 20 19 21 15 22 23 17
P.vulgaris 16 17 15 12 14 18 19 20 17 16 12 14 15 18 17
E.coli 14 13 15 12 11 16 20 13 14 15 17 19 21 21 23
A.niger 17 18 15 12 14 17 15 19 20 18 21 22 0 0 0







COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-I
Section - I : Antimicrobial activity of 1-Aryl-3-(1',N-pheny-3'-p-tolyl-pyrazol-4'-yl)-2-propene-1-ones
1i (21) 1i (20) 1g (19) 1g (20) 1i (20)
1j (20) 1k (21) 1h (20) 1l (19) 1k (21)
1l (22)
Ampicillin 23 22 15 21 -
Amoxicillin 22 23 18 21 -
Norfloxacin 24 17 17 23 -
Penicillin 25 24 20 19 -
Greseofulvin - - - - 25
B. mega S. aureus P. vulgaris E. coli A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity







Amongst nitrogen containing five membered heterocycles, pyrazolines
have proved to be the most useful framework for biological activities, pyrazolines
have attracted attention of medicinal chemists for both with regard to heterocyclic
chemistry and the pharmacological activities associated with them. In 1967 Jarobe,
reviewed the chemistry of pyrazolines, which  have been studied extensively for
their biodyndmic behaviour160 and industrial applications161.
SYNTHETIC ASPECT :
Different methods for the preparat ion of 2-pyrazol ine derivat ives
documented in literature are as follows.
1. 2-Pyrazolines can be constructed by the cyclocondensation of chalcones
with hydrazine hydrate162.
2. 2-pyrazolines can also be prepared by the condensation of chalcone
dibromide with hydrazines163.
3. 2-pyrazolines can be synthesised by the cycloaddition of diazomethane to
substituted chalcones.164
4. Dipolar cycloaddition of nitrilimines of dimethyl fumarate, fumaronitrile and













5. Epoxidation of chalcones have epoxy ketones which reacted with hydrazine
and phenyl hydrazine to give pyrazolines166.
Furthermore, B. Gyassi et al.167 investigated the one pot synthesis  of some
pyrazolines in dry media under microwave irradiation S. Paul et al.168 and Dandia
Anshu et al.169 have also described the microwave assisted synthesis of 2-
pyrazolines.
MACHANISIM
The following mechanism seems to be operable for the condensation of
chalcones with hydrazine hydrate.170
Nucleophilic attack by hydrazine at the β-carbon of the α,β-unsaturated
carbonyl system forms species (II), in which the -ve charge is mainly accomodated
by the electronegative oxygen attom.
Proton transfer from the nitrogen to -ve oxygen produces an intermediate
enol which simultaneously ketonises to ketoamine (III). Another intramolecular
nucleophilic attack by the primary amino group of ketoamine on its carbonyl











( i ) proton transfer





















carbonyl amine (IV). The later with a hydroxy group and amino group on the
same carbon lose water molecule to yield the pyrazolines.
THERAPEUTIC IMPORTANCE



















S. S. Sonarc et al.191 have synthesised-3-(2-acetoxy-4-methoxyphenyl)-5-
(substituted phenyl)-pyrazolines and tested their antimicrobial activity. H. H.
Parekh192 et al. have also synthesised some new pyrazolines as an antimicrobial
agent. G. N. Mishirika et al.193 have also prepared 2-pyrazolines of salicyclic
acid (II) possessing antimicrobial properties.
41Pyrazolines...
Tunfawy, Atif and co-workers194 have patented 3-methyl-4'-(substituted
phenylazo)-pyrazol-5-ones as antibacterial agents.
Moreover F. Manna and co-worker195 have described 1-acetyl-5-(2'-
bromophenyl)-4,5-dihydro-3-(2'-hydroxyphenyl)-1H-pyrazol ines and i ts
derivatives which acts as potent antiinflammatory, analgesic and antipyratic
agents. Udupi R. H. and Bhatt A. R.196 have reported the synthesis and biological
activity of Mannich bases of certain 1,2-pyrazolines. Nugent Richard197
investigated pyrazolines bis phosphonate ester as novel antiinflammatory and
antiarthritic agent.
Fuche Rainer et al.198 have prepared some new 1H-pyrazoline derivatives
and reported them as pesticides. Furthermore, Tsubai et al.199 have synthesised
some new (phenylcarbamoyl) pyrazolines as an insecticides and at 40%
concentration shows 100% mortality of spodopetra litura larve after seven drops.
Moreover, T. M. Stivensen et al.200 have also investigated N-substituted
pyrazoline type insecticides. Tanka Katsohori201 have patented pyrazoline
derivatives as herbicides and Johannes et al.202 as insecticides. Moritaz Z. and
Hadol203 to investigated a semi emperial molecular orbital study on the reaction
of aminopyrazolinyl azodye with singlet molecular oxygen.
Shivnanda M. K. and co-workers204 have prepared substituted pyrazolines
and reported their antibacterial activity. E. Palska et al.205 have prepared 3,5-
diphenyl-2-pyrazolines (I) and cited their antidepressant activity.
B. Shivrama et al.206,207 have synthesised pyrazolines as antibacterial
agents. Hiremath S. P. et al.208 have synthesised pyrazolines as analgesics
antiinflammatory and antimicrobial agents. Malhotra V. et al.209 have synthesised
new pyrazolines as a cardiovascular agents (II).
42Pyrazolines...
Almstead J. et al.210 have prepared pyrazolines as vascularization agents.
Guniz Kuchkguzel et al.211 have synthesised pyrazolines as a antimicrobial and
anticonvalsant agents. Gulhan T. Z. and co-workers212 have prepared pyrazolines
as a hypotensive agent. Shulabh Sharma et al.213 have synthesised pyrazolines
and tested their antiinflammatory activity (III).
Ashok Kumar et al.214 have synthesised pyrazolines as anticonvulsant
agents (IV). Maurer Fritz et al.215 have synthesised pyrazoles and screened for
their pesticidal activity.
CONTRIBUTION FROM OUR LABORATORY
Parekh et al.216 have prepared 1-Acetyl-5-aryl-3-[3,-(3,4-dihydro-2-methyl-
4-one-3-quinozalinyl)-phenyl]-2-pyrazolines which possess antimicrobial activity.
Several pyrazolines bearing thymol moiety were evaluated for their ability as
potent antimicrobial by Hansa Parekh et al.217 Parekh and co-workers218 have
prepared pyrazolines from arsanilic acid for their antimicrobial activity. Parekh
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Parikh et al.221 have synthesised some antimicrobial pyrazolines. Parekh
et al.222 have synthesised phenyl pyrazolines bearing quinoline (x) moiety and
described their antimicrobial activity. Parikh et al.223 have synthesised and tested
the antimicrobial activity of p-(2',5'-dibromo benzene sulphonamido)-phenyl-5-
aryl-1H/acetyl/phenyl-2-pyrazolines (XI).
Recent ly,  A .  R.  Parekh and co-workers  have synthes i sed newer
pyrazolines 224-229 with variety of biological activity.
In view of therapeutic activities shown by pyrazolines, it was contemplated
to synthesise some new pyrazolines in search of agents possessing higher
biological activity with least side effect have been described as under.
SECTION-I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
3-ARYL-5-[1'-N-PHENYL-3'-p-TOLYL-PYRAZOL-4'-
YL]-PYRAZOLINES
SECTION-II : SYNTHESIS AND THERAPEUTIC EVALUATION OF
1,N-ACETYL-3-ARYL-5-[1',N-PHENYL-3'-p-TOLYL-
PYRAZOL-4'-YL]-PYRAZOLINES


















(VI)R = Aryl, R1 = COCH3, Ph
SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-ARYL-5-[1'-N-
PHENYL-3'-p-TOLYL-PYRAZOL-4'-YL]-PYRAZOLINES
Pyrazolines are endowed with valid antimicrobial activities. Looking at their
versatile therapeutic importance and with an aim to getting beter drug, it was
considered worthwile to synthesise some new pyrazolines bearing 1,N-phenyl-
3-p-tolyl-4-formyl-pyrazole nucleus. The preparation of 3-aryl-5-(1',N-phenyl-
3-p-tolyl-pyrazol-4'-yl)-pyrazolines (IV) have been under taken by cyclo
condensation of type (I) with hydrazine hydrate.
The constitution at the systhesised products have been characterised using
elemental analyses, infrared & 1H nuclear magnetic resonance spectroscopy and
mass spectrometry also. In mass spectrometry the m/z value indicate the molecular
weight., i.e. when R=4-methoxyphenyl, molecular weight=408, m/z=408.
All the compounds have been screend for their invitro biological activity
like antitubercular activity towards a strain of Mycobacterum tubarculosis
H37 Rv at  a concontration of 6.25 µg/ ml using Rifampin as a standard drug,
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concelteation of 40 µg/
ml. The biological activity of the synthesised compounds have been compared
with standard drugs. Some compounds have been found to have good and
equivalent activity as compared to the known antibiotics recorded on Page No.53.
The details have been cited in Part-I, Section-I(D).













IR SPECTRAL STUDY OF 3-p-TOLYL-5-(1',N-PHENYL-3'-p-TOLYL-PYRAZOL-4'-YL)-
PYRAZOLINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2960 2975-2950 614
-CH3 C – H str.(sym.) 2866 2880-2860 "
C= H i.p. (def.) 1460 1470-1435 "
C-H o.o.p. (def.) 1357 1395-1370 "
Aromatic C – H str. 3030 3090-3030 615
C = C str. 1581 1585-1570 "
1496 1520-1480 "
C – H i.p. (def.) 1128 1125-1090 "
1041 1070-1000 "
C–H  o.o.p. (def.) 821 835-810 "
Pyrazole C = N str 1595 1610-1590 616
moiety C – N str. 1220 1230-1020 "
Pyrazole C – N str. 1180 1230-1020 616
ring N – H str. 3315 3320-3140 "
C=N str. 1612 1650-1550 "







PMR SPECTRAL STUDY OF 3-p-ANISYL-5-[1,N-PHENYL-3'-p-TOLYL-PYRAZOL-4'-YL]-
PYRAZOLINE
Internal Standard : TMS; Solvent : CDCl3  : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 2.40 3H singlet Ar-CH3 -
2. 3.0-3.08 1H d,d Ar-Hk -
3. 3.4-3.49 1H d,d Ar-Hl -
4. 3.82 3H singlet Ar-OCH3 -
5. 5.08-5.14 1H d,d Ar-Hm -
6. 6.89-6.92 2H doublet Ar-H g,g' Jgf=8.8
7. 7.25-7.28 2H doublet Ar-H f,f' Jfg=8.8
8. 7.23-7.28 1H multiplet Ar-Hc -
9 .7.39-7.45 2H triplet Ar-H b,d -
10. 7.59-7.63 4H multiplet Ar-H i,i',a,e Jij=8.7
11. 7.70-7.72 2H doublet Ar-H j,j' Jji=8.7

















































































































SYNTHESIS AND THERAPEUTIC EVALUATION OF 3-ARYL-5-(1',N-
PHENYL-3'-p-TOLYL-PYRAZOL-4'-YL)-PYRAZOLINES
[A] Synthesis of N- Phenylamine-α-methyl-α-p-tolyl azomethine
See, Part-I, Section-I (A)
[B] Synthesis of 1,N-Phenyl-3-p-tolyl-4-formyl pyrazole
See, Part-I, Section-I (B)
[C] Synthesis of 1-(p-Methoxyphenyl)-3-(1'-N-phenyl-3'-p-tolyl-pyrazol-
4'-yl)-2-propene-1-one
See, Part-I, Section-I (C)
[D] Synthesis of-3-(p-methoxyphenyl)-5-(1',N-phenyl-3'-p-tolyl-pyrazol-
4'-yl)-pyrazoline
A mixture of 1-(p-methoxyphenyl)-3-[1',N-phenyl-3'-p-tolyl-pyrazol-4'-yl]-
2-propene-1-one (3.94 g., 0.01M), hydrazine hydrate (2 ml, 0.04 M) in 30ml
methanol was refluxed for 12 hrs. The product obtained was filtered, washed
with hot methanol and crystallized from dioxan. Yield, 81% (3.3 gm), m.p.158oC.
(C26H24N4O  ; Found : C, 76.45%; H, 5.92% : N, 13.72%; Required : C,
76.35%; H, 5.87%; N, 31.71%). TLC Solvent system : Acetone : Benzen (4:6).
Similarly other pyrazolines have been undertaken. The physical data are
recorded in Table No. 2.
[E] Antimicrobial activity of 3-Aryl-5-(1',N-phenyl-3'-p-tolyl-pyrazol-4'-
yl)-pyrazolines
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solution are reported in Graphical Chart No. 2.
[F] Antitubercular activity of 3-Aryl-5-(1',N-phenyl-3'-p-tolyl-pyrazol-
4'-yl)-pyrazolines
The antitubercular screening of the compounds of type (II), were carried
out by TAACF, the Southern Research Institute, U.S.A. as described in Part-I,























2a C6H5- C25H22N4 378 182 0.62 56 14.80 14.73
2b 4-Br-C6H4- C25H21N4Br 457 145 0.65 59 12.25 12.18
2c 4-Cl-C6H4- C25H21N4Cl 412 167 0.64 58 13.57 13.53
2d 4-F-C6H4- C25H21N4F 396 204 0.60 60 14.13 14.11
2e 4-CH3-C6H4- C26H24N4 392 184 0.69 62 14.27 14.26
2f 4-OCH3-C6H4- C26H24N4O 408 158 0.58 81 13.72 13.75
2g 2-OH-C6H4- C25H22N4O 394 115 0.56 60 14.20 14.26
2h 4-OH-C6H4- C25H22N4O 394 135 0.60 71 14.20 14.13
2i 4-NH2-C6H4- C25H23N5 393 140 0.50 73 17.80 17.74
2j 3-NO2-C6H4- C25H21N5O2 423 200 0.56 74 16.54 16.51
2k 4-NO2-C6H4- C25H21N5O2 423 215 0.55 70 16.54 16.58
2l 2-C4H3S- C23H20N4S 384 184 0.65 58 14.57 14.53
































B.mega 19 20 15 17 14 12 18 17 14 16 23 13 23 22 24
S.aureus 15 12 14 13 18 17 21 20 18 15 14 19 22 23 17
P.vulgaris 19 14 12 13 18 17 19 15 20 12 14 18 15 18 17
E.coli 13 17 18 15 19 22 13 14 16 18 19 20 21 21 23
A.niger 14 18 15 12 20 21 15 17 22 13 14 18 0 0 0







COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-I
Section - I : Antimicrobial activity of 3-Aryl-5-(1,N-pheny-3'-p-tolyl-pyrazol-4'-yl)-pyrazolines
2b (20) 2g (21) 2a (19) 2f (22) 2e (20)
2k (23) 2h (20) 2g (19) 2l (20) 2f (21)
2i (20) 2i (22)
Ampicillin 23 22 15 21 -
Amoxicillin 24 23 18 21 -
Norfloxacin 24 17 17 23 -
Penicillin 25 24 20 19 -
Greseofulvin - - - - 25
B. mega S. aureus P. vulgaris E. coli A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity





@98% inhibi t ion
TABLE NO.2a : DATA OF IN VITRO EVALUATION OF ANTITUBERCULAR  ACTIVITY
TAACF, Southern Research Institute Dr. A. R. Parikh
Primary Assay Summary Report Saurashtra University
Sample Corp Where,R= Supplier Assay MTb MIC % comment
ID ID Strain µg/ml Inhib
171857 KB-62 C6H5- Sau.uni Alamar H37Rv >6.25 65
171858 KB-63 4-Br-C6H4- Sau.uni Alamar H37Rv >6.25 70  ''
171859 KB-64 4-Cl-C6H4- Sau.uni Alamar H37Rv >6.25 76  ''
171860 KB-65 4-CH3-C6H4- Sau.uni Alamar H37Rv >6.25 75  ''
171861 KB-66 4-OCH3-C6H4- Sau.uni Alamar H37Rv >6.25 86  ''
171862 KB-67 2-OH-C6H4- Sau.uni Alamar H37Rv >6.25 77  ''
171863 KB-68 4-OH-C6H4- Sau.uni Alamar H37Rv >6.25 43  ''
171864 KB-69 4-NH2-C6H4- Sau.uni Alamar H37Rv >6.25 11  ''
171865 KB-70 3-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 0  ''
171866 KB-71 4-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 80  ''
171867 KB-72 4-F-C6H4- Sau.uni Alamar H37Rv >6.25 43  ''
171868 KB-73 2-C4H3S- Sau.uni Alamar H37Rv >6.25 0  ''
NIAID/ Southern Research institute/ GWL Hansen's Center/








SYNTHESIS AND THERAPEUTIC EVALUATION OF 1,N-ACETYL-3-
ARYL-5-(1',N-PHENYL-3'-p-TOLYL-PYRAZOL-4'-YL)-PYRAZOLINES
Pyrazoline derivatives represent one of the most active classes of compounds
having a wide spectrum of biological activities. Looking to the interesting
properties of pyrazolines it was considered worthwhile to synthesise a series of
pyrazolines of type (III) for obtaining biologically potent agents which were
prepared by reacting chalcones with hydrazine hydrate in glacial acetic acid.
The constitution of the systhesised products have been characterised by using
elemental analyses, infrared & 1H-nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. In mass spectrometry m/z value indicate
the molecular weight, i.e. when R=4-hydroxyphenyl, molecular weight=436, m/
z=437 (m+1)
All the compounds have been screend for their invitro biological activity
like antitubercular activity towards a strain of Mycobacterum tubarculosis
H37 Rv at  a concontration of 6.25 µg/ ml using Rifampin as a standard drug,
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concelteation of 40 µg/
ml. The biological activity of the synthesised compounds have been compared
with standard drugs. Some compounds have been found to have good and
equivalent activity as compared to the known antibiotics recorded on Page No.63.

















IR SPECTRAL STUDY OF 1,N-ACETYL-3-p-BROMOPHENYL-5-(1',N-PHENYL-3'-p-
TOLYL-PYRAZOL-4'-YL)-PYRAZOLINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2970 2975-2950 614
-CH3 C – H str.(sym.) 2860 2880-2860 "
C – H i.p. (def.) 1452 1470-1435 "
C-H o.o.p. (def.) 1357 1395-1370 "
Aromatic C – H str. 3057 3090-3030 615
C = C str. 1504 1520-1480 "
C – H i.p. (def.) 1108 1125-1090 "
1064 1070-1000 "
C–H o.o.p. (def.) 823 835-810 "
Pyrazole C = N str 1593 1610-1590 616
moiety C – N str. 1228 1230-1020 "
Pyrazole C – N str. 1228 1230-1020 "
ring N – H str. 3315 3320-3140 "
C=N str. 1612 1650-1550 "
– C–H (CH2) str. 2860 2850-2790 "
N–COCH3 str. 1651 1660 618,619









PMR SPECTRAL STUDY OF 1,N-ACETYL-3-PHENYL-5-[1',N-PHENYL-3'-p-TOLYL-
PYRAZOL-4'-YL]-PYRAZOLINE
Internal Standard : TMS; Solvent :CDCl3 : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 2.36 3H singlet Ar-CH3 -
2. 2.46 3H singlet Ar-COCH3 -
3. 3.05-3.13 1H d,d, Ar-Hk -
4. 3.57-3.66 1H d,d Ar-Hl -
5. 5.86-5.91 1H d,d Ar-Hm -
6. 7.23-7.26 2H doublet Ar-H f,f' Jfg= 9
7. 7.35-7.49 5H multiplet Ar-H (n to r) -
8. 7.57-7.76 7H multiplet Ar-H (a to e)& g,g' Jgf=9
































































































































SYNTHESIS AND THERAPEUTIC EVALUATION OF 1,N-ACETYL-3-
ARYL-5-(1',N-PHENYL-3'-p-TOLYL-PYRAZOL-4'-YL)-PYRAZOLINES
[A] Synthesis of N-Phenylamine-α-methyl-α-p-tolyl azomethine
See, Part-I, Section-I (A)
[B] Synthesis of 1,N-Phenyl-3-p-tolyl-4-formyl pyrazole
See, Part-I, Section-I (B)
[C] Synthesis of 1-(p-methoxyphenyl)-3-(1'-N-phenyl-3'-p-tolyl-pyrazol-
4'-yl)-2-propene-1-one
See, Part-I, Section-I (C)
[D] Synthesis of 1,N-Acetyl-3-phenyl-5-(1',N-phenyl-3'-p-tolyl-pyrazol-
4'-yl)-pyrazoline
A mixture of 1Phenyl-3-(1',N-phenyl-3'-p-tolyl-pyrazol-4'-yl)-2-propene-1-
one (3.64 g, 0.01M), in 25 ml of ethanol, hydrazine hydrate (0.5gm, 0.01M) and
glacial acetic (10 ml) was refluxed for 8 hrs. The content were poured into ice
and the product was isolated and crystallised from ethanol + dioxane (2 : 2).
Yield, 72% (3.0 gm).  m.p. 193oC. (C27H24N4O ; Found: C,77.12%; H, 5.75%;
N, 13.32%;  Required : C, 77.8%; H, 5.71%; N, 13.27%).
TLC solvent system Acetone : Benzene  (1:9).
Similarly other acetyl pyrazolines were prepared. The physical data are
recorded in Table No. 3
[E] Antimicrobial activity of 1,N-Acetyl-3-aryl-5-(1',N-phenyl-3'-p-tolyl-
pyrazol-4'-yl)-pyrazolines
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The  zone of inhibition of the test solution are recorded in Graphical Chart No. 3.
[F] Antitubercular activity of 1,N-Acetyl-3-aryl-5-(1',N-phenyl-3'-p-tolyl-
pyrazol-4'-yl)-pyrazolines
The antitubercular screening of the compounds of type (II), were carried























3a C6H5- C27H24N4O 420 193 0.63 72 13.32 13.27
3b 4-Br-C6H4- C27H23N4OBr 499 135 0.81 60 11.22 11.17
3c 4-Cl-C6H4- C27H23N4OCl 454.5 172 0.69 57 12.31 12.29
3d 4-F-C6H4- C27H23N4OF 438 235 0.55 61 12.78 12.73
3e 4-CH3-C6H4- C28H26N4O 434 205 0.72 71 12.89 12.86
3f 4-OCH3-C6H4- C28H26N4O2 450 184 0.57 64 12.44 12.41
3g 2-OH-C6H4- C27H24N4O2 436 175 0.50 62 12.84 12.79
3h 4-OH-C6H4- C27H24N4O2 436 190 0.48 65 12.84 12.77
3i 4-NH2-C6H4- C27H25N5O 435 203 0.55 59 16.08 16.03
3j 3-NO2-C6H4- C27H23N5O3 465 210 0.44 61 15.04 15.00
3k 4-NO2-C6H4- C27H23N5O3 465 195 0.56 62 15.04 15.07
3l 2-C4H3S- C25H22N4OS 426 145 0.71 70 13.14 13.11
































B.mega 20 18 17 12 14 16 18 19 13 14 14 19 23 22 24
S.aureus 17 18 15 14 13 12 11 13 19 18 22 20 22 23 17
P.vulgaris 17 18 15 17 12 13 14 17 19 17 18 14 15 18 17
E.coli 16 17 15 12 19 18 18 17 19 21 16 18 21 21 23
A.niger 18 17 12 14 19 23 22 14 14 15 18 22 0 0 0







COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-II
Section - II : Antimicrobial activity of 1,N-Acetyl-3-aryl-5-(1',N-phenyl-3'-p-tolyl-pyrazol-4'-yl)-pyrazolines
3a (20) 3k (22) 3b (18) 3e (19) 3f (23)
3h (19) 3l (20) 3i (19) 3i (19) 3g (22)
3l (19) 3k (18) 3j (21) 3l (22)
Ampicillin 23 22 15 21 -
Amoxicillin 22 23 18 21 -
Norfloxacin 24 17 17 23 -
Penicillin 25 24 20 19 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity





@98% inhibi t ion
TABLE NO.3a : DATA OF IN VITRO EVALUATION OF ANTITUBERCULAR  ACTIVITY
TAACF, Southern Research Institute Dr. A. R. Parikh
Primary Assay Summary Report Saurashtra University
Sample Corp Where,R= Supplier Assay MTb MIC % comment
ID ID Strain µg/ml Inhib
171833 KB-38 C6H5- Sau.uni Alamar H37Rv >6.25 48
171834 KB-39 4-Br-C6H4- Sau.uni Alamar H37Rv >6.25 75  ''
171835 KB-40 4-Cl-C6H4- Sau.uni Alamar H37Rv >6.25 83  ''
171836 KB-41 4-CH3-C6H4- Sau.uni Alamar H37Rv >6.25 35  ''
171837 KB-42 4-OCH3-C6H4- Sau.uni Alamar H37Rv >6.25 0  ''
171838 KB-43 2-OH-C6H4- Sau.uni Alamar H37Rv >6.25 46  ''
171839 KB-44 4-OH-C6H4- Sau.uni Alamar H37Rv >6.25 20  ''
171840 KB-45 4-NH2-C6H4- Sau.uni Alamar H37Rv >6.25 24  ''
171841 KB-46 3-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 3  ''
171842 KB-47 4-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 52  ''
171843 KB-48 4-F-C6H4- Sau.uni Alamar H37Rv >6.25 0  ''
171844 KB-49 2-C4H3S- Sau.uni Alamar H37Rv >6.25 96  ''
NIAID/ Southern Research institute/ GWL Hansen's Center/










SYNTHESIS AND THERAPEUTIC EVALUATION OF 1,N-PHENYL-3-
ARYL-5-(1',N-PHENYL-3'-p-TOLYL-PYRAZOL-4'-YL)-PYRAZOLINES
Looking to the interesting therapeutic activities of pyrazoline, it was
considered worthwhile to synthesise compounds bearing 1,N-phenyl-3-p-tolyl-
4-formyl-pyrazole moiety linked to the pyrazoline nucleus. Pyrazolyl pyrazoline
of type (IV) have been prepared by the action of 1-aryl-3-(1',N-phenyl-3-p-tolyl-
pyrazole-4'-yl)-2-propene-1-one with phenylhydrazine in presence of piperidine.
The constitution of the systhesised products have been characterised by using
elemental analyses, infrared & 1H nuclear magnetic resonance spectroscopy and
it was confirmed by mass spectrometry also. In massspectrometry m/z value
indicate the molecular weight, i.e. when R=4-methoxyphenyl, molecular
weight=484 gm, m/z=484 (m).
All the compounds have been screend for their invitro biological activity
like antitubercular activity towards a strain of Mycobacterum tubarculosis
H37 Rv at  a concontration of 6.25 µg/ ml using Rifampin as a standard drug,
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concelteation of 40 µg/
ml. The biological activity of the synthesised compounds have been compared
with standard drugs. Some compounds have been found to have good and
equivalent activity as compared to the known antibiotics recorded on Page No.73.















IR SPECTRAL STUDY OF 1,N-PHENYL-3-p-ANISYL-5-(1',N-PHENYL-3'-p-TOLYL-
PYRAZOL-4'-YL)-PYRAZOLINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2958 2975-2950 614
-CH3 C – H str.(sym.) 2860 2880-2860 "C – H i.p. (def.) 1452 1470-1435 "
C-H o.o.p. (def.) 1384 1395-1370 "
Aromatic C – H str. 3060 3090-3030 615
C = C str. 1581 1585-1570 "
1498 1520-1480 "
C – H i.p. (def.) 1126 1125-1090 "
1062 1070-1000 "
C–H o.o.p. (def.) 833 835-810 "
Pyrazole C = N str 1598 1610-1590 616
moiety C – N str. 1215 1230-1020 "
Pyrazole C – N str. 1176 1230-1020 616
ring N – H str. 3315 3320-3140 "
C=N str. 1581 1650-1550 "
– C–H (CH2) str. 2860 2850-2790 "
Ether C–O–C str. (asym.) 1249 1260-1220 616








PMR SPECTRAL STUDY OF 1,N-PHENYL-3-ANISYL-5-[1',N-PHENYL-3'-p-TOLYL-
PYRAZOL-4'-YL]-PYRAZOLINE
Internal Standard : TMS; Solvent :CDCl3 DMSOd6: Instrument : BRUKER Spectrometer (300
MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1. 2.43 3H singlet Ar-CH3 -
2. 3.16-3.23 1H d,d Ar-Hk -
3. 3.76-3.86 1H d,d, Ar-Hl -
4. 3.83 3H singlet Ar-OCH3 -
5. 5.41-5.47 1H d,d Ar-Hm -
6. 6.74-6.78 1H triplet Ar-Hp -
7. 6.88-6.91 2H doublet Ar-H g,g' Jgf=8.7
8. 7.05-7.07 2H doublet Ar-H f,f' Jfg=8.7
9. 7.14-7.23 3H multiplet Ar-H (a,c,e) -
10. 7.30-7.33 2H doublet Ar-H i,i' Jij=8.4
11. 7.36-7.38 2H triplet Ar-H (b,d) -
12. 7.61-7.64 4H doublet Ar-H j, j' & n,r Jji=8.4
13. 7.67-7.70 2H triplet Ar-H (o, g) -



























































































































































SYNTHESIS AND THERAPEUTIC EVALUATION OF 1,N-PHENYL-3-
ARYL-5-(1',N-PHENYL-3'-p-TOLYL-PYRAZOL-4'-YL)-PYRAZOLINES
[A] Synthesis of N-Phenylamine-α-methyl-α-p-tolyl-azomethine
See, Part-I, Section-I (A).
[B] Synthesis of 1,N-Phenyl-3-p-tolyl-4-formyl pyrazole
See, Part-I, Section-I (B)
[C] Synthesis of 1-(p-Methoxyphenyl)-3-(1'-N-phenyl-3'-p-tolyl-pyrazol-
4'-yl)-2-propene-1-one
See, Part-I, Section-I (C)
[D] Synthesis of-1,N-phenyl-3-(p-Methoxyphenyl)-5-(1',N-phenyl-3'-p-
tolyl-pyrazol-4'-yl)-pyrazoline
A mixture of 1-(p-methoxyphenyl)-3-(1',N-phenyl-3'-p-tolyl-pyrazol-4'-yl)-
2-propene-1-one (3.94gm, 0.01M), phenylhydrazine (1.08g, 0.01m) in 25 ml
methanol was refluxed for 12 hrs. in presence of basic catalyst like piperidine.
The reaction product was poured into ice, crude product was isolated, crystallized
from Dioxan. Yield, 86% (4.15 gm), m.p. 214o C; (C32H28N4O ; Found : C,
79.31%; H, 5.82%; N, 11.56%; Required : C, 79.28%; H, 5.79%; N, 11.51%).
TLC solvent system Acetone : Benzene (3:7).
Similarly other acetyl pyrazolines were prepared. The physical data are
recorded in Table No. 4
[E] Antimicrobial activity of 1,N-Phenyl-3-aryl-5-(1',N-phenyl-3'-p-tolyl-
pyrazol-4'-yl)-pyrazolines
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The  zone of inhibition of the test solutions are recorded in Graphical Chart No. 4
[F] Antitubercular activity of 1,N-Phenyl-3-aryl-5-(1',N-phenyl-3'-p-
tolyl-pyrazol-4'-yl)-pyrazolines
The antitubercular screening of the compounds of type (II), were carried























4a C6H5- C31H26N4 454 158 0.63 66 12.23 12.19
4b 4-Br-C6H4- C31H25N4Br 453.4 115 0.69 61 10.50 10.53
4c 4-Cl-C6H4- C31H25N4Cl 489 135 0.60 63 11.46 11.43
4d 4-F-C6H4- C31H25N4F 472.5 230 0.70 67 11.86 11.82
4e 4-CH3-C6H4- C32H28N4 468.6 215 0.72 59 11.96 11.93
4f 4-OCH3-C6H4- C32N28N4O 484.7 214 0.54 86 11.56 11.51
4g 2-OH-C6H4- C21H26N4O 470.5 158 0.67 69 11.91 11.87
4h 4-OH-C6H4- C31H26N4O 470.5 170 0.81 70 11.91 11.86
4i 4-NH2-C6H4- C31H27N5 469.5 185 0.64 71 11.91 11.85
4j 3-NO2-C6H4- C31H25N5O2 499.5 220 0.66 70 14.02 14.05
4k 4-NO2-C6H4- C31H25N5O2 499.5 175 0.59 64 14.02 13.98
4l 2-C4H3S- C29H24N4S 460.5 156 0.65 59 12.16 12.11
































B.mega 14 16 18 19 21 18 15 12 13 16 17 22 23 22 24
S.aureus 13 15 18 20 21 14 16 18 17 15 14 19 22 23 17
P.vulgaris 18 17 13 15 18 19 16 17 12 13 15 19 15 18 17
E.coli 21 18 13 14 18 18 19 12 14 16 17 20 21 21 23
A.niger 12 15 17 21 23 19 20 12 14 16 17 19 0 0 0






COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-II
Section - III : Antimicrobial activity of 1,N-Phenyl-3-aryl-5-(1',N-phenyl-3'-p-tolyl-pyrazol-4'-yl)-pyrazolines
4e (21) 4d (20) 4f (19) 4a (21) 4d (21)
4l (22) 4e (21) 4l (19) 4g (19) 4e (23)
4l (20) 4g (20)
Ampicillin 23 22 15 21 -
Amoxicillin 22 23 18 21 -
Norfloxacin 24 17 17 23 -
Penicillin 25 24 20 19 -
Greseofulvin - - - - 25
B. mega S. aureus P. vulgaris E. coli A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity





@98% inhibi t ion
TABLE NO.4a : DATA OF IN VITRO EVALUATION OF ANTITUBERCULAR  ACTIVITY
TAACF, Southern Research Institute Dr. A. R. Parikh
Primary Assay Summary Report Saurashtra University
Sample Corp Where,R= Supplier Assay MTb MIC % comment
ID ID Strain µg/ml Inhib
171869 KB-74 C6H5- Sau.uni Alamar H37Rv >6.25 80
171870 KB-75 4-Br-C6H4- Sau.uni Alamar H37Rv >6.25 76  ''
171871 KB-76 4-Cl-C6H4- Sau.uni Alamar H37Rv >6.25 52  ''
171872 KB-77 4-CH3-C6H4- Sau.uni Alamar H37Rv >6.25 71  ''
171873 KB-78 4-OCH3-C6H4- Sau.uni Alamar H37Rv >6.25 76  ''
171874 KB-79 2-OH-C6H4- Sau.uni Alamar H37Rv >6.25 82  ''
171875 KB-80 4-OH-C6H4- Sau.uni Alamar H37Rv >6.25 45  ''
171876 KB-81 4-NH2-C6H4- Sau.uni Alamar H37Rv >6.25 99  ''
171877 KB-82 3-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 76  ''
171878 KB-83 4-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 73  ''
171879 KB-84 4-F-C6H4- Sau.uni Alamar H37Rv >6.25 56  ''
171880 KB-85 2-C4H3S- Sau.uni Alamar H37Rv >6.25 65  ''
NIAID/ Southern Research institute/ GWL Hansen's Center/











Pyrimidine derivatives which occur in natural products230 like nucleic acids
and vitamin-B and remarkable pharmaceutical importence bacause of their
biological activities.231-235 Several analogs of nucleic acids have been used as
compounds that interefere with the synthesis and functioning of nucleic acids,
and example is fluorouracil which has been used in cancer treatment. Pyrimidines
are among those molecules that make life possible as being some of the building
blocks of DNA and RNA.
Some pyrimidines of physiological ly as wel l  as pharmacological ly
importance are as under : e.g., cytosine, bedmethrin (I), blasticidin (II).
Synthetic pyrimidinone derivatives contribute much to the searchable
literature of pyrimidinone derivatives, in huge libraries owing to their wide
applicability in different fields.
SYNTHETIC ASPECT :
Different methods for the synthesis of pyrimidinones have been cited in the
literature.236






















Pyrimidinone derivatives have proven to be of great importance in exhibiting
and enhancing the biological activities. Such as,
1. Antitumor238
2. Carcinostatic239



















































































Moreover Azaryan et al.262 have synthesised pyrimidine diones as antitumor
agent. Krivongov and co-worker263 have synthesised pyrimidinone derivatives
possessing immunotropic and antiinflammatory activity. Omer M. T. and co-
worker264 have prepared some new pyrimidinone derivatives showed moderate
activity against the growth of Bacillus subtilis, Staphylococus aureus and
Aspergillus niger. Amuti Kofies et al.265 have suggested that pyrimidinones as
herbicidal and plant growth regulators.
K. Mogilaiah266 have prepared spiropyrimidinones as antibacterial. Drewes
and Wilhelm267 have synthesised pyrimidinone as herbicidal agents. Timothy
and co-worker268 have suggested imidazolyl pyrimidinones as antiviral.
Nagamatsu et al.269 have prepared some new triazolo [3,4,-c] pyrimidinone as
xanthin oxidase inhibitors. Andree Roland et al.270 have prepared oxazolyl uracil
as herbicidal and insecticidal. Yari M. M and co-worker271 have investigated the
pyrimidinone derivatives which possess calcium antagonist activity.
Bruce M. A and co-worker272 prepared the dihydro pyrimidinones as NPY
antagonists. Sidler and Larsen273 have reported pyrimidinone derivatives useful
as an α-adrenergic receptor antagonists. Mona Mahran and co-worker274 have
synthesised pyrimidine derivatives as potent antimicrobial and antitumor agents.
Saxena A. K. and co-worker275 have prepared 2,6-di substituted pyrimidinone
as CNS agent.
77Pyrimidinones...
Pyrimidinone derivatives276,277 have found to be calcium channel blocker
Barbuliene M. M. et al.278 have synthesised pyrimidinones as antiinflammatory
agent.
Recently, Amjad Ali et al.279 have synthesised new fused pyrimidinones as
antimicrobial agents. Abd El-Galil et al.280 have synthesised pyrimidinone as
androgenic anabolic and antiinflammatory agents. Martin Balli et al.281 have
synthesised pyrimidines as endothelin receptor antagonists.
Patricia F. F. et al.282 have synthesised and screened for their leukocyte
functions inhibitor activity. Dumas Jacques et al.283 have synthesised
pyrimidinones and tested their hyderproliterative disorder activity. Adenosine
receptor antagonists pyrimidinones have been prepared by Tsutsumi Hideo et al.284
Thus, diverse biological activities have been encountered in compounds
containing pyrimidinone ring system. To further assess the potential of such type
of compounds, study of pyrimidinone have been carried out as under.
SECTION-I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
2-ARYLIMINO-3,N-ARYL-5-(1 ' -N-PHENYL-3 ' -p-
T O L Y L - 4 ' - P Y R A Z O L Y L M E T H I N O ) - 4 -
THIAZOLIDINONES






SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-ARYLIMINO-
3,N-ARYL-5-(1',N-PHENYL-3'-p-TOLYL-4'-PYRAZOLYLMETHINO)-4-
THIAZOLIDINONES
Recently much interest has been focused on the synthesis and biodynamic
activities of arylidene and it is a good synthon for various heterocyclic rings.
With a view of obtaing compounds having better therapeutic activities, we have
synthesised 2-Arylimino-3-N-aryl-5-[1',N-phenyl-3'-p-tolyl-4'-pyrazolylmethino]-
4-thiazolidinoes by the condensation of pyrazole aldehyde with various
thiazolidinone compounds.
The constitution of the systhesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and mass spectrometry. In a mass spectrometry the m/z value indicate the
molecular weight, i ,e, when R=p-methoxyphenyl molecular weight=572.
m/z=573 (m+l).
All the compounds have been screend for their invitro biological activity
like  antibacterial activity towards Gram positive and Gram negative bacterial
strains and antifungal activity towards Aspergillus niger at a concelteation of
40 µg/ml. The biological activity of the synthesised compounds have been
compared with standard drugs. Some compounds have been found to have good
and equivalent activity as compared to the known antibiotics recorded on Page
No.73. The details have been cited in Part-I, Section-I(D).













































































R = ArylType (V)
IR SPECTRAL STUDY OF 2-p-TOLYLIMINO-3,N-p-TOLYL-5-(1',N-PHENYL-3'-p-TOLYL-
PYRAZOLMETHINO)-4'-THIAZOLIDINONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2964 2975-2950 614
-CH3 C – H str.(sym.) 2879 2880-2860 "
C – H i.p. (def.) 1434 1470-1435 "
C-H o.o.p. (def.) 1363 1395-1370 "
Aromatic C – H str. 3053 3090-3030 615
C = C str. 1500 1520-1480 "
C – H i.p. (def.) 1105 1125-1090 "
1028 1070-1000 "
C–H o.o.p. (def.) 833 835-810 "
Pyrazole C = N str. 1596 1610-1590 616
moiety C – N str. 1213 1230-1020 "
Thiazolidinone C = O str. 1706 1760-1655 620
ring C – S – C str. 688 700-600 "
C–N str. 1164 1220-1020 "











PMR SPECTRAL STUDY OF  2,p-TOLYLIMINO-3,N-p-TOLYL-5-[1',N-PHENYL-3'-P-
TOLYL-4'-PYRAZOLYLMETHINO]-4-THIAZOLIDINONE
Internal Standard : TMS; Solvent : CDCl3: Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 2.42 3H singlet Ar-CH3 -
2. 3.82 3H singlet Ar-OCH3 -
3. 3.84 3H singlet Ar-OCH3 -
4. 6.92-6.93 4H doublet Ar-H i,i' & l,l' -
5. 7.02-7.05 2H doublet Ar-H g,g' Jgf=8.8
6. 7.27-7.30 2H doublet Ar-H f,f' Jfg=8.8
7. 7.34-7.39 3H multiplet Ar-H (a,c,e) -
8. 7.45-7.51 2H triplet Ar-H (b,d) -
9 7.55-7.57 2H doublet Ar-H j j' Jji=8.1
10. 7.74-7.77 2H doublet Ar-H m,m' Jml=8.2
11. 7.85 1H singlet Ar-Hh -






























































































































































[A] Preparation of N1, N3-Bis-p-anisyl thiourea285
A mixture of-p-Anisidine (0.2 mol), carbondisulphide (7 ml, 0.1 mol) and
absolute alcohol (20 ml) was heated on waterbath for 5-6 hrs. On completion of
reaction, the excess of carbon disulphide and alcohol was removed by distillation.
The product was treated with dilute hydrochloric acid to remove excess of amine
present and crude product was isolated crystallised in rectified spirit. Yield, 85%;
m.p. 123, (C15H16N2O2S ; Found : C,62.48% ; H,5.59% ; N,9.71% ; Required:
C,62.46% ; H,5.54% ; N, 9.73%).
TLC solvent system : Ethylacetate : Hexane (2:8).
[B] Preparation of 2-p-anisylamino-3-p-anisyl-5H-4-thiazolidinones286
A solution of N1, N3-Bis-p-Anisyl thiourea (0.01 mol) and chloro acetic
acid (0.94g, 0.01mol) in glacial acetic acid (15 ml) was refluxed with fused sodium
acetate (1.25 g, 0.015 mol) for 5 hrs.The reaction product was poured in water,
kept overnight, crude product was isolated, crystallised from acetic acid. Yield,
78% ; m.p. 178oC. (C17H16N2O3S; Found : C,62.18%; H, 4.91%; N,8.53%;
Required : C, 62.17%; H, 4.87%; N, 8.52%).
TLC solvent system : Acetone : Benzene : (0.5 : 9.5).
[C] Preparation of 1,N-Phenyl-3-p-tolyl-4-formyl-pyrazole
See, Part-I, Section-I (B)
[D] Preparation of 2-(p-Methoxyphenylimino)-3-(p-methoxyphenyl)-5-
(1',N-phenyl-3'-p-tolyl-4'-pyrazolylmethino)-4-thiazolidinone
A mixture of 2-(p-Methoxyphenylimino)-3-(p-methoxyphenyl)-5H-4-
85
thiazolidinone (3.28gm; 0.01mol), 1,N-phenyl-3-p-tolyl-4-formyl-pyrazole
(2.62g, 0.01m) and fused sodium acetate (1.25 g, 0.015 g) was refluxed in glacial
acetic acid (15 ml) for 4-5 hrs. Cooled poured into water and treat with ammonia
to remove excess of glacial acetic acid. The solid thus obtained was filtered,
washed, dr ied and crysta l l i sed f rom acet ic  acid.  Yie ld,  71% (4.1gm),
m.p. 220o C. (C34H28N4O3S) Found : C,71.31%; H, 4.93%; N, 9.78; Required
: C, 71.27%; H, 4.88%; N, 9.71%).
TLC solvent system : Ethylacetate : Hexane (1.5 : 8.5).
Similarly, other thiazolidinones were prepared. The physical data are
recorded in Table No. 5.
[E] Antimicrobial activity of 2-Arylimino-3-aryl-5-(1',N-phenyl-3'-p-
tolyl-4'-pyrazolylethino-4'-yl)-4-thiazolidinones
Antimicrobial testing was carried out as described in Par-I, Section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 5
[F] Antitubercular activity of 2-Arylimino-3-aryl-5-(1',N-phenyl-3'-p-
tolyl-4'-pyrazolylethino-4'-yl)-4-thiazolidinones
The antitubercular screening of the compounds of type (V), were carried
out by TAACF, the Southern Research Institute, U.S.A. as described in Part-I,
























5a C6H5- C32H24N4O5 512 183 0.50 60 10.93 10.88
5b 2-OCH3-C6H4- C34H28N4O3S 572 165 0.55 65 9.78 9.73
5c 4-OCH3-C6H4- C34H28N4O3S 572 220 0.63 71 9.78 9.71
5d 2-NO2-C6H4- C32H22N6O5S 602 130 0.52 59 13.95 13.90
5e 3-NO2-C6H4- C32H22N6O5S 602 115 0.48 64 13.95 13.91
5f 4-NO2-C6H4- C32N22N6O5S 602 165 0.52 52 13.95 13.92
5g 4-Cl-C6H4- C32H22N4OSCl2 581 125 0.60 58 9.63 9.65
5h 4-COOH-C6H4- C34H24N4O5S 600 205 0.50 62 9.33 9.36
5i 3-CH2-C6H4- C34H28N4OS 540 137 0.57 71 10.36 10.31
5j 4-CH3-C6H4- C34H28N4OS .540 145 0.48 70 10.36 10.33
5k 3-Cl,4-F--C6H3- C32H20N4OSCl2F2 617 165 0.53 58 9.07 9.02
5l 2,5-(Cl)2-C6H3- C32H20N4OSCl4 650 127 0.47 66 8.61 8.64
































B.mega 19 17 15 14 13 12 18 18 17 19 22 17 23 22 24
S.aureus 22 13 15 18 17 14 20 21 13 18 19 14 22 23 17
P.vulgaris 16 19 15 13 12 14 16 19 13 17 14 15 15 18 17
E.coli 13 15 18 19 17 14 16 15 12 13 21 17 21 21 23
A.niger 12 15 14 18 23 17 19 15 17 16 18 13 0 0 0






COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-III
Section - I : Antimicrobial activity of 2-Arylimino-3,N-aryl-5-(1',N-phenyl-3'-p-tolyl-4'-pyrazolylmethino)-
4-thiazolidinone
5a (19) 5a (22) 5b (19) 5d (19) 5e (23)
5j (19) 5g (20) 5h (19) 5k (21) 5g (19)
5k (22) 5h (21)
Ampicillin 23 22 15 21 -
Amoxicillin 22 23 18 21 -
Norfloxacin 24 17 17 23 -
Penicillin 25 24 20 19 -
Greseofulvin - - - - 25
B. mega S. aureus P. vulgaris E. coli A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity





@98% inhibi t ion
TABLE NO.5a : DATA OF IN VITRO EVALUATION OF ANTITUBERCULAR  ACTIVITY
TAACF, Southern Research Institute Dr. A. R. Parikh
Primary Assay Summary Report Saurashtra University
Sample Corp Where,R= Supplier Assay MTb MIC % comment
ID ID Strain µg/ml Inhib
171845 KB-50 C6H5- Sau.uni Alamar H37Rv >6.25 58
171846 KB-51 2-OCH3-C6H4- Sau.uni Alamar H37Rv >6.25 21  ''
171847 KB-52 4-OCH3-C6H4- Sau.uni Alamar H37Rv >6.25 17  ''
171848 KB-53 2-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 0  ''
171849 KB-54 3-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 23  ''
171850 KB-55 4-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 27  ''
171851 KB-56 4-Cl-C6H4- Sau.uni Alamar H37Rv >6.25 17  ''
171852 KB-57 4-COOH-C6H4- Sau.uni Alamar H37Rv >6.25 15  ''
171853 KB-58 3-CH3-C6H4- Sau.uni Alamar H37Rv >6.25 52  ''
171854 KB-59 3-Cl, 4-F-C6H3- Sau.uni Alamar H37Rv >6.25 26  ''
171855 KB-60 2,5-(Cl)2-C6H3- Sau.uni Alamar H37Rv >6.25 0  ''
171856 KB-61 4-CH3-C6H4- Sau.uni Alamar H37Rv >6.25 3  ''
NIAID/ Southern Research institute/ GWL Hansen's Center/










SYNTHESIS AND THERAPEUTIC EVALUATION OF 6-ARYLIMINO-
7,N-ARYL-2-OXO-4-[1',N-PHENYL-3'-p-TOLYL-PYRAZOL-4'-YL)1,2,3,4-
TETRAHYDRO THIAZOLIDINO-[4,5-d]-PYRIMIDINES
In the past years considerable evidence has been accumulated to
demonstrate the efficiency of pyrimidinones. To further assess the potential of
such as class of compounds, it was considered worthwhile to synthesise
compounds  bear ing  2-ary l imino-3-ary l -5- (1 ' ,N-pheny l -3 ' -p- to ly l -4 ' -
pyrazolylmethino)-4-thiazolidinone nucleus linked to the pyrimidinone nucleus.
Pyrimidinones of type (VI) have been prepared by the condensation of 2-
arylimino-3-aryl-5H-4-thiazolidinone, 1,N-phenyl-3-p-tolyl-4-formyl-pyrazole
and urea in presence of catalytic amount of conc. HCl as shown under.
The constitution of the systhesised products have been characterised by using
elemental analyses, infrared spectroscopy and 1H nuclear magnetic resonance
spectroscopy and further confirmed by mass spectrometry. In mass spectrometry
m/z value indicate the molecular weight i.e., when R=4-chlorophenyl, molecular
weight=623, m/z=625 (m+2).
All the newly synthesized compounds have been screened for their invitro
biological assay like antibacterial activity towards Gram positive and Gram
negative bacterial strains and antifungal activity towards Aspergillus niger at a
concenteution of 40 µg/ml. The biological activities of the synthesised compounds
have been compared with standard drugs, recorded on Page No.99. The details
have been cited in Part-I, Section-I(D).




























IR SPECTRAL STUDY OF 6-p-TOLYLIMINO-7,N-p-TOLYL-2-OXO-4-(1',N-PHENYL-3'-p-
TOLYL-PYRAZOL-4'-YL)-1,2,3,4-TETRAHYDRO-THIAZOLIDINON-[4,5-d]-PYRIMIDINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2916 2975-2950 614
-CH3 C – H str.(sym.) 2858 2880-2860 "
C – H i.p. (def.) 1444 1470-1435 "
C-H o.o.p. (def.) 1361 1395-1370 "
Aromatic C – H str. 3028 3090-3030 615
C = C str. 1502 1520-1480 "
C – H i.p. (def.) 1143 1125-1090 "
1053 1070-1000 "
C–H o.o.p. (def.) 825 835-810 "
Pyrazole C = N str. 1596 1610-1590 616
moiety C – N str. 1209 1230-1020 "
Pyrimidine C = O str. 1683 1750-1600 621
ring N –H str. 3404 3500-3350 "
C–N str. 1616 1650-1550 "
C–S–C str. 759 800-700 "
Ether C–S–C str. (asym.) 1265 1275-1200 "













PMR SPECTRAL STUDY OF 6-p-TOLYLIMINO-7,N-p-TOLYL-2-OXO-4-(1',N-PHENYL-3'-
p-TOLYL-PYRAZOL-4'-YL)-THIAZOLIDINO-(4,5-d)-PYRIMIDINE
Internal Standard : TMS; Solvent :CDCl3 : DMSOd6 Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 2.35 3H singlet Ar-CH3 -
2. 2.42 3H singlet Ar-CH3 -
3. 2.43 3H singlet Ar-CH3 -
4. 6.84-6.87 2H doublet Ar-H  g,g' Jgf=8.2
5. 7.16-7.18 2H doublet Ar-H  j,j' Jji=9
6. 7.29-7.31 2H doublet Ar-H  m,m' Jml=8.0
7. 7.33-7.36 1H multiplet Ar-Hc -
8. 7.47-7.50 2H doublet Ar-H  f,f' Jfg= 8.2
9. 7.53-7.57 2H multiplet Ar-H (b, d) -
10. 7.72-7.73 2H doublet Ar-H (a, e) -
11. 7.77-7.80 2H doublet Ar-H  l,l' Jlm=8.0
12. 7.87-7.90 2H doublet Ar-H  i,i' Jij=9
13. 8.20 1H singlet Ar-Hh -


































































































































































































SYNTHESIS AND THERAPEUTIC EVALUATION OF 6-ARYL-IMINO-
7,N-ARYL-2-OXO-4-[1',N-PHENYL-3'-p-TOLYL-PYRAZOL-4'-YL]-1,2,3,4-
TETRAHYDRO-THIAZOLIDINO-[4,5-d]-PYRIMIDINES
[A] Preparation of 2-p-Tolylimino-3-aryl-5H-4-thiazolidinone
See, Part-III, Section-I (B)
[B] Preparation of 6-(p-Mehylphenylimino)-7,N-(p-tolyl-2-oxo-4-(1',N-
phenyl-3'-p-tolyl-pyrazol-4'-yl)-1,2,3,4-tetrahydro-thiazolidino-[4,5-
d]-pyrimidine
A mixture of 2-(p-Methylphenylimino)-3-(p-tolyl-5H-4-thiazolidinone
(2.96g, 0.01M) 1,N-phenyl-3-p-tolyl-4-formyl-pyrazole (2.62g, 0.01mol) and area
(0.60g, 0.01 mol) were taken in methanol (30 ml) and a catalytic amount of conc
HCl (0.5 ml) was added. The reaction mixture was refluxed on water bathe for 5
hrs. cooled and poured into water. The solid thus obtained was filtered, isolated
and product was crystallised from methanol-DMF.  Yield, 76% (4.4 gm), m.p.
198oC; (C35H30N6O5, Found : C, 72.14%; H, 5.19%; N, 14.42%; Required :
C, 72.11%; H, 5.14&; N, 14.50%).
TLC solvent system  : Acetone : Bezene (2.5 : 7.5).
Similarly other pyrimidinones were prepared. The physical data are recorded
in Table No. 6.
[C] Antimicrobial activity of 6-Arylimino-7,N-aryl-2-oxo-4-(1',N-phenyl-
3'-p-tolyl-pyrazol-4'-yl)-1,2,3,4-tetrahydro-thiazolidino-(4,5-d)-
pyrimidines
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
























6a C6H5- C33H26N6OS 554 125 0.49 61 15.15 15.13
6b 2-OCH3-C6H4- C35H30N6O3S 614 115 0.51 63 13.67 13.63
6c 4-OCH3-C6H4- C35H30N6O3S 614 145 0.73 69 13.67 13.73
6d 2-NO2-C6H4- C33H24N8O5S 644 210 0.68 59 17.38 17.33
6e 3-NO2-C6H4- C33H24N8O5S 644 185 0.51 68 17.38 17.29
6f 4-NO2-C6H4- C33H24N8O5S 644 225 0.44 52 17.38 17.31
6g 4-Cl-C6H4- C33H24N6OSCl2 623 125 0.64 60 13.48 13.53
6h 4-COOH-C6H4- C35H26N6O5S 642 160 0.62 63 13.08 13.01
6i 3-CH3-C6H4- C35H30N6OS 582 165 0.66 58 14.42 14.50
6j 4-CH3-C6H4- C35H30N6OS 582 198 0.70 76 14.42 14.47
6k 3-Cl,4-F--C6H3- C33H22N6OSCl2F2 659 112 0.60 66 12.74 12.69
6l 2,5-(Cl)2-C6H3- C33H22N6OSCl4 692 124 0.51 59 12.14 12.09
































B.mega 13 18 19 19 18 17 18 21 15 14 19 22 23 22 24
S.aureus 20 15 17 14 12 18 19 20 17 16 18 14 22 23 17
P.vulgaris 17 14 12 15 13 18 19 17 14 15 17 18 15 18 17
E.coli 12 15 17 18 19 20 13 14 17 18 19 22 21 21 23
A.niger 13 18 17 19 20 14 15 12 16 18 22 19 0 0 0







COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-III
Section - II : Antimicrobial activity of 6-Arylimino-7,N-aryl-2-oxo-4-(1',N-phenyl-3'-p-tolyl-pyrazol-4'-yl)-
1,2,3,4-tetrahydro-thiazolidino-[4,5-d]-pyrimidin
6h (21) 6a (20) 6f (18) 6f (20) 6f (20)
6l (22) 6h (20) 6g (19) 6k (19) 6k (22)
6l (18) 6l (22)
Ampicillin 23 22 15 21 -
Amoxicillin 22 23 18 21 -
Norfloxacin 24 17 17 23 -
Penicillin 25 24 20 19 -
Greseofulvin - - - - 25
B. mega S. aureus P. vulgaris E. coli A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity






Thiourea (NH2-C-NH2), itself was one of the first new drug employed to
depress, the clinically over active thyroid in thyrotxiocsis287 but some of the
cyclic thioureides have since been found better suited. The most valuable have
been thiouracil and it's derivatives. All of these are prone of produce adverse
reduction in susceptible patients and found more potent and less likely to produce
side effects and is being used widely.288
SYNTHETIC ASPECT
First primary synthesis of thiopyrimidine derivatives from aliphatic fragments
was carried out by frankland and kolbs in 1848. Since than a many distinct primary
synthetic methods have been devised289-293. Different methods reported are
as under.
(1) By the condensation of β-keto ester with N-methyl thiourea.294
(2) By the condensation of β-dinitriles with thiourea and guanidines.295
(3) By the condensat ion of  β -a ldehydroni tr i le  wi th formamidine and
thiourea.296
(4) 2-Mercaptopyrimidines can be synthesised by G. N. Anderson297 through
condensation of thiourea and substituted β-ketoester in presence of sodium
ethoxide
(5) Bigineli298 investigated that an aromatic aldehyde with β-ketoester and urea
or thiourea and yield pyrimidine derivatives (I).
S












(6) Wang Jinjun299 have prepared some new benzo [c]  pyrano [4,3-d]
pyrimidine derivatives (II).
Reaction between arylidene and thiourea, in first step thiourea react with
α,β-unsaturated system and electron take place due to the more electro negativity
of oxygen atom than carbon atom. So oxygen get negative charge, it condense
with amine of thiourea and remove water molecule, so formation of thiopyrimidine
is one type of cycloaddition process.
THERAPEUTIC IMPORTANCE
Thiopyrimidines are excellent reservoir of bioactive substance. In the past
years, the literature enriched with progressive findings about the synthesis and
pharmacological action of thiopyrimidine derivatives. The important activities
are as under.
(1) Antifilarial300
(2) Antiinflammatory and analgesic301-303
(3) Antileishmanial304-306
(4) Anticancer and Herbicidal307-308
(5) Antineoplastic309,310
(6) Antiviral and Antitumor311
(7) Antimicrobial312
(8) Anti AIDS and Antitumor313
(9) Antitubercular314

















Moreover, V. Peesapati et al.320 and H. Allimony321 have synthesised
thiopyrimidine derivatives documented as potent antimicrobial agent. Mahran
and co-workers322 have prepared heterocyclic system containing thiopyrimidene
nucleus as antimicrobial and antitumor agent S. A. Swelam323 have reported
furopyrimidines which possess antitumor activity. Soneyashi et al.324 prepared
thiopyrimidine nucleosides as anticancer and antiviral agents. Danel and co-
workers325 have synthesised some novel pyrimidine derivatives possissing Anti
HIV activity.
Corbett et al.326 assessed thiopyrimidine derivatives as HIV reverse
transcript as inhibitors. Thiopyrimidine derivatives are having numerous
pharmacological activity like antagonists327 antiinflammatory and analgesic328
antileishmanial329 and antimicrobial330 activity. C. J. Shishoo and co-
workers331 have reported thiopyrimidine derivatives as receptor antagonists.
Recently, Abou El-Foltoh et al.332 synthesise thiopyrimidine derivatives which
showed anticancer activity.
V. Peesapati et al.333 and Allimony have synthesised thiopyrimidine
derivatives334 documented as potent antimicrobial agent. B. J. Ghiya et al.335
have synthesised mercapto pyrimidine derivatives and screened for their
anticancer, antitubercular and anti HIV activities. S. A. Swelam336 have reported
furo pyrimidines which possess antitumor activity. Mohammad Nasrk et al337
prepared thiopyrimidine nucleosides as antiviral agent. Danel et al.338 have
synthesised some novel thiopyrimidine derivatives possessing anti HIV activity.
W. Jeffrey et al.339 assessed thiopyrimidine derivatives as HIV reverse
transcriptase inhibitors. Thiopyrimidine derivatives are having numerous
pharmacological activity like antagonists340, analgesic,341 antileishmania342
and antimicrobial343 activity. Biginelli et al.344 have reported thiopyrimidine
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derivatives (III) as a antimicrobial agent.
Gangjee Aleem345 prepared 5-thiapyrimidines (IV) as dihydrotoluate
reductase inhibitors.
Fggenweiler, Hans Michael et al.346 prepared thieno [2,3-d] pyrimidine
derivatives as phosphodiesterase v inhibitors. Patricia Fernandez-Ferri et al.347
synthesised pyrimidine derivatives as inhibitors of some leukocyte functions.
Yadav Bodke & S. S. Sangapure348 prepared pyrimidine derivatives as
biologically active compounds. Dumas et al.349 prepared some pyrimidine
derivatives as for treatment of hyperproliferative disorders. Chamanlal J. Shishoo
et al.350 prepared pyrimidine derivatives as antihistaminic activity.
CONTRIBUTION FROM OUR LABORATORY
A. R. Parikh, H. H. Parekh and their co-worker have synthesised the
thiopyrimidines351,352.
Thus the important role played by thiopyrimidine nucleus for various
physiological activities prompted us to explore thiopyrimidine chemistry by
synthesising its derivatives bearing different heterocyclic ring system of therapeutic
importance, in order to achieve compounds having better drug potential which
has described as under.























SYNTHESIS AND THERAPEUTIC EVALUATION OF 6-ARYLIMINO-7,N-
ARYL-2-THIO-4-[1',N-PHENYL-3'-p-TOLYL-PYRAZOL-4'-YL)1,2,3,4-
TETRAHYDRO-THIAZOLIDINO-[4,5-d]-PYRIMIDINES
Thiopyrimidines represent one of the most active classes of compounds
possessing a wide spectrum of biological activities, such as significant in vitro
activity against unrelated DNA and RNA viruses including Polio and Herper
Viruses, diuretic, antitubercular spermidical etc. These valid observation led us
to synthesis thiopyrimidines of type (VII) by condensation of 1,N-phenyl-3-p-
tolyl-4-formyl pyrazole with different thiazolidinones and thiourea in presence
of HCl as catalyst.
The constitution of the systhesised products have been characterised by using
elemental analyses, infrared spectroscopy & 1H nuclear magnetic resonance
spectroscopy and mass spectrometry etc. In mass spectrometry the m/z, value
indicate the molecular weight i.e., when R=3-Cl, 4-F-phenyl molecular
weight=675, m/z=675 (m).
The products have been screened for their in vitro biological assay like
antimicrobial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/
ml. The biological activities of the synthesised compounds were compared with
standard drugs,  recorded on Page No.112. The details have been cited in Part -
I, Section-I (D).


























IR SPECTRAL STUDY OF 6-p-TOLYLIMINO-7,N-p-TOLYL-2-THIO-4-(1',N-PHENYL-3'-p-
TOLYL-PYRAZOL-4'-YL)-1,2,3,4-TETRAHYDRO-THIAZOLIDINON-[4,5-d]-PYRIMIDINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2918 2975-2950 614
-CH3 C – H str.(sym.) 2854 2880-2860 "
C – H i.p. (def.) 1448 1470-1435 "
C-H o.o.p. (def.) 1363 1395-1370 "
Aromatic C – H str. 3024 3090-3030 615
C = C str. 1537 1585-1570 "
1502 1520-1480 "
C – H i.p. (def.) 1051 1070-1000 "
C–H o.o.p. (def.) 821 835-810 "
Pyrazole C = N str. 1598 1610-1590 616
moiety C – N str. 1226 1230-1220 "
Pyrimidine C = S str. 725 750-700 620
ring N –H str. 3404 3500-3350 "
C–N str. 1537 1650-1550 "
C–S–C str. 781 800-700 "
Ether C–S–C str. (asym.) 1267 1275-1200 "













PMR SPECTRAL STUDY OF 6-p-TOLYLIMINO-7,N-p-TOLYL-2-THIO-4-[1',N-PHENYL-
3'-p-TOLYL-PYRAZOL-4'-YL]-THIAZOLIDINO-(4,5-D)-PYRIMIDINE
Internal Standard : TMS; Solvent :CDCl3: Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 2.35 3H singlet Ar-CH3 -
2. 2.40 3H singlet Ar-CH3 -
3. 2.41 3H singlet Ar-CH3 -
4. 6.87-6.89 2H doublet Ar-H g,g' Jgf=8.1
5. 7.15-7.18 2H doublet Ar-H j,j' Jji=7.8
6. 7.26-7.29 2H doublet Ar-H m,m' Jml=8.1
7. 7.33-7.35 5H multiplet Ar-H f,f', a,c,e Jfg=8.1
8. 7.44-7.48 2H triplet Ar-H (b,d) -
9. 7.54-7.57 2H doublet Ar-H l,l' Jlm=8.1
10. 7.72-7.75 2H doublet Ar-H i,i' Jij=7.8
11. 7.85 1H singlet Ar-Hk -
















































































































































































SYNTHESIS AND THERAPEUTIC EVALUATION OF 6-ARYLIMINO-
7,N-ARYL-2-THIO-4-[1',N-PHENYL-3'-p-TOLYL-PYRAZOL-4'-YL]-1,2,3,4-
TETRAHYDRO-THIAZOLIDINO-[4,5-d]-PYRIMIDINES
[A] Preparation of 1,N-Phenyl-3-p-tolyl-4-formyl-pyrazole
See, Part-I, Section-I(B)
[B] Preparation of N1,N3-Bis-p-tolyl thiourea
See, Part-III, Section-I (A)
[C] Preparation of 2-p-Tolylimino-3-p-tolyl-5H-4-thiazolidinones
See, Part-III, Section-I (B)
[D] Preparation of 6-(p-Tolylimino)-7,N-(p-tolyl)-2-thio-4-[1',N-phenyl-
3'-p-tolyl-pyrazol-4'-yl]-1,2,3,4-tetrahydro-thiazolidino-[4,5-d]-
pyrimidine
A mixture of 2-(p-Tolylimino)-3-(p-tolyl)-5H-4-thiazolidinone (2.96gm,
0.01M), 1,N-phenyl-3-p-tolyl-4-formyl-pyrazole (2.62g, 0.01mol) and thiourea
(0.76gm, 0.01M) were taken in methanol (30 ml) and a catalytic amount of conc.
HCl (0.5 ml) was added. The reaction mixture was refluxed on water bath for 5
hrs., cooled and poured into water. The solid thus obtained was filtered, isolated
and product was crystallyssed from methanol-DMF. Yield, 68% (4.1 gm), m.p.
192oC, (C35H30N6S2 ; Found ; C, 70.20%; H, 5.05%; N, 14.04%; Required :
C, 70.16%; H, 5.02%; N, 14.01%). TLC solvent system Acetone : Benzene (2:8).
Similarly other thiopyrimidines were prepared. The physical data are
recorded in Table No. 7
[E] Antimicrobial activity of 6-Arylimino-7,N-aryl-2-thio-4-[1',N-
phenyl-3'-p-tolyl-pyrazol-4'-yl]-1,2,3,4-tetrahydro-thiazolidino-[4,5-
d]-pyrimidines
Antimicrobial testing was carried out as described in Part-I, Section-I (D).























7a C6H5- C33H26N6S2 570 210 0.56 59 14.73 14.76
7b 2-OCH3-C6H4- C35H30N6O2S2 630 135 0.66 62 13.32 13.37
7c 4-OCH3-C6H4- C35H30N6O2S2 630 164 0.48 64 13.32 13.28
7d 2-NO2-C6H4- C33H24N8O4S2 660 195 0.51 65 16.96 16.91
7e 3-NO2-C6H4- C33H24N8O4S2 660 127 0.52 68 16.96 16.94
7f 4-NO2-C6H4- C33H24N8O4S2 660 138 0.50 58 16.96 16.99
7g 4-Cl-C6H4- C33H24N6S2Cl2 639 156 0.58 60 13.14 13.18
7h 4-COOH-C6H4- C35H26N6O4S2 658 165 0.59 61 12.76 12.71
7i 3-CH3-C6H4- C35H30N6S2 598 172 0.55 66 14.08 14.00
7j 4-CH3-C6H4- C35H30N6S2 598 192 0.60 68 14.08 14.01
7k 3-Cl,4-F--C6H3- C33H22N6S2Cl2F2 675 120 0.63 60 12.44 12.34
7l 2,5-(Cl)2-C6H3- C33H22N6S2Cl4 708 146 0.65 71 11.86 11.82
































B.mega 13 18 19 19 18 16 18 21 11 13 19 22 23 22 24
S.aureus 13 12 14 15 11 13 17 19 18 17 21 19 22 23 17
P.vulgaris 12 11 18 13 12 11 16 19 13 15 18 17 15 18 17
E.coli 11 15 16 18 17 14 19 21 16 14 13 12 21 21 23
A.niger 12 14 21 12 19 18 22 17 14 13 15 17 0 0 0







COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-IV
Section - I : Antimicrobial activity of 6-Arylimino-7,N-aryl-2-thio-4-(1',N-phenyl-3'-p-tolyl-pyrazol-4'-yl)-
1,2,3,4-tetrahydro-thiazolidino-[4,5-d]-pyrimidin
7h (21) 7h (19) 7c (18) 7g (19) 7e (19)
7l (22) 7k (21) 7h (19) 7h (21) 7g (22)
7l (19) 7k (18)
Ampicillin 23 22 15 21 -
Amoxicillin 22 23 18 21 -
Norfloxacin 24 17 17 23 -
Penicillin 25 24 20 19 -
Greseofulvin - - - - 25
B. mega S. aureus P. vulgaris E. coli A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity






2-Aminopyrimidine is the most important member of all the diazine as this
ring system occurs widely in living organisms. Pyrimidine was first isolated by
Gabriel and Colman in 1899. 2-Amino pyrimidine and its derivatives represent
one of the most active class of compounds possessing a wide spectrum of
biological activities.
SYNTHETIC ASPECT :
1. The reaction of chalcone with guanidine hydrochloride in presence of
potassium t-butoxide in t-butanol yielded corresponding 2-amino pyrimidine
derivatives353.
2. Abd-El-galil E. Amr354 synthesised aminopyrimidines by the reaction of
chalcones with guanidine hydrochloride in the presence of NaOH.
3. Rasaki355 synthesised 2-amino-pyrimidine by the reaction of chalcone


































































. . . .
THERAPEUTIC IMPORTANCE




3. Inhibitor of celular proliferation359





8. Tyrosine kinase Inhibitor364
9. Adrenaline α-receptor bloker365
Large no of drugs possess aminopyrimidine ring system. Well-known
antimalarial agents like trimethoprim (I) and pyrimethamine (II) possess
pyrimidine ring system.
Hisaki Masakutsu366 synthesised some aminopyrimidines which are useful
in the t reatment of  rotavira l  d iseases.  Robson C. et  a l .367 prepared
aminopyrimidine derivatives as antifungal agents in P9P and MRP over expressive
tumor cell lines. Leanne M. et al.368 have prepared aminopyrimidines and













Yamada K369 synthesised some aminopyrimidines and tested for endothelin
antagonists. Suto, M. et al.370 prepared some amino pyrimidines which found to
possess antiinflammatory, anticancer, antirheumatoid activities. Gangjee A. et
al.371 synthessied aminopyrimidines which possess antitumor activity. Ugarkar
B. et al.372 found aminopyrimidines in the inhibition of cardiovascular and
ceribrovascular disorders.
Hernandez et al.373 and Secrist J. et al.374 prepared aminopyrimidines
showing antitumor activity. Glazier A. et al.375 and Singh J.376 found
aminopyrimidines as antiviral agents. Pan S.377 prepared 2-methylthio-4-amino-
6-(3,5-diacetylphenyl-amino)-pyrimidines. Which show anti HIV activity in H9
cell cultures. Aminopyrimidines derivatives also possess antimicrobial378, anti
HIV379 and antitumor380 activities.
Looking to the deversified activities exhibited and in continuation of our
work on the synthesis of biologically active heterocycles, the synthesis and
biological screening of aminopyrimidine derivatives have been described as
under. Bargiotti, Alberto et al.381 prepared 1,7-disubstituted guanine derivatives
for their therapeutic use as telomerase inhibitors & anticancer agent. Bargiatli,
Alberto et al.382 prepared disubstitute 7,9-guaninium halides as telomerase
inhibitors.
Peirre C. Wyss et al.383 prepared some novel aminopyrimidines as novel
dihydrofolate reductase inhibitors. Aleem Gangjee et al.384 prepared some
aminopyrimidines as potential dual inhibitors of thymidylate synthase &
dihydrofalate reductase & as potential antitumor agents. Andre Rosowasky et
al.385 prepared aminopyrimidines as potent & selective inhibitors of dihydrofalate
reductase from three major opportunistic pathogens of AIDS. Tsutumi et al.386
prepared aminopyrimidines as addenosine receptor antagonists.
Looking to the interesting properties of Aminopyrimidines, we have
synthesised some new aminopyrimidines, which have been described as under.
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SECTION - I
SYNTHESIS AND THERAPEUTIC EVALUATION OF 6-ARYLIMINO-7,N-
ARYL-2-AMIN0-4- [1 ' ,N-PHENYL-3 ' -p -TOLYL-PYRAZOL-4 ' -YL) -
THIAZOLIDINO-[4,5-d]-PYRIMIDINES
Many aminopyrimidine derivatives are reported to possess different
biological activities. In view of these reports, it was considered worthwhile to
synthesise some new 6-arylimino-7,N-aryl-2-amino-4-(1',N-phenyl-3'-p-tolyl-
pyrazol-4'-yl)-thiazolidino-[4,5-d]-pyrimidines of type (VIII) to study their
biological activities. Aminopyrimidine derivatives have been prepared by
condensat ion of  1,N-phenyl-3-p-toly l -4- formyl-pyrazole wi th di f ferent
thiazolidinones and guanidine hydrochloride in presence of HCl as catalyst.
The constitution of the systhesised products have been characterised using
elemental analyses, infrared spectroscopy & 1H nuclear magnetic resonance
spectroscopy and mass spectrometry. In mass spectrometry the m/z value indicate
the molecular weight i.e., when R=2-Nitrophenyl, molecular weight=641, m/
z=641 (m).
The products have been screened for their in vitro biological assay like
antimicrobial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/
ml. The biological activities of the synthesised compounds were compared with
standard drugs, recorded on Page No.124. The details have been cited in Part -
I, Section-I (D).



























IR SPECTRAL STUDY OF 6-p-TOLYLIMINO-7,N-p-TOLYL-2-AMINO-4-(1',N-PHENYL-3'-
p-TOLYL-PYRAZOL-4'-YL)-THIAZOLIDINON-[4,5-d]-PYRIMIDINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2918 2975-2950 614
-CH3 C – H str.(sym.) 2854 2880-2860 "
C – H i.p. (def.) 1448 1470-1435 "
C-H o.o.p. (def.) 1411 1395-1370 "
Aromatic C – H str. 3024 3090-3030 615
C = C str. 1537 1585-1570 "
1502 1520-1480 "
C – H i.p. (def.) 1051 1070-1000 "
C–H o.o.p. (def.) 821 835-810 "
Pyrazole C = N str. 1596 1610-1590 616
moiety C – N str. 1207 1230-1220 "
Pyrimidine N–H str. (–NH2) 3404 3500-3350 620
ring N –H str. 1686 1750-1650 "
C–N str. 1539 1650-1550 "
C–S–C str. 758 800-700 "
Ether C–S–C str. (asym.) 1267 1275-1200 "












PMR SPECTRAL STUDY OF 6-p-TOLYLIMINO-7,N-p-TOLYL-2-AMINO-4-[1',N-PHENYL-
3'-p-TOLYL-PYRAZOL-4'-YL]-THIAZOLIDINO-(4,5-d)-PYRIMIDINE
Internal Standard : TMS; Solvent :CDCl3 DMSOd6 : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 2.33 3H singlet Ar-CH3 -
2. 2.41 3H singlet Ar-CH3 -
3. 2.43 3H singlet Ar-CH3 -
4. 6.86-6.88 2H doublet Ar-H g,g' Jgf=8.1
5. 7.16-7.19 2H doublet Ar-H j,j' Jji=8.4
6. 7.28-7.31 2H doublet Ar-H m,m' Jml=8.1
7. 7.33-7.38 2H multiplet Ar-H (a, e) -
8. 7.47-7.52 2H triplet Ar-H (b,d) -
9. 7.54-7.58 3H doublet Ar-H f,f' & c Jfg=8.1
10. 7.74-7.77 2H doublet Ar-H l,l' Jlm=8.1
11. 7.82-7.84 2H doublet Ar-H i,i' Jij=8.4
12. 8.11 1H singlet Ar-Hh -





















































































































































































































































SYNTHESIS AND THERAPEUTIC EVALUATION OF 6-ARYL-IMINO-7,N-
ARYL-2-AMINO-4- [1 ' ,N-PHENYL-3 ' -p -TOLYL-PYRAZOL-4 ' -YL] -
THIAZOLIDINO-[4,5-d]-PYRIMIDINES
[A] Preparation of 1,N-Phenyl-3-p-tolyl-4-formyl pyrazole
See, Part-I, Section-I (B)
[B] Preparation of 2-p-Tolylimino-3-p-tolyl-5H-4-thiazolidinones
See, Part-III, Section-I (B)
[C] Preparation of 6-(p-Tolylimino)-7,N-(p-tolyl)-2-amino-4-[1',N-
phenyl-3'-p-tolyl-pyrazol-4'-yl]-thiazolidino-[4,5-d]-pyrimidine
A mixture of 2-(p-Tolylimino)-3-(p-tolyl)-5H-4-thiazolidinone (2.96gm,
0.01M), 1,N-phenyl-3-p-tolyl-4-formyl-pyrazole (2.62g, 0.01mol) and guanidine
hydrochloride (0.10gm, 0.01mol) were taken in methanol (30 ml) and a catalytic
amount of conc. HCl (0.5 ml) was added. The reaction mixture was refluxed on
water bath for 5 hrs., cooled and poured into water. The solid thus obtained was
filtered, isolated and product was crystallissed from methanol-DMF. Yield, 79%
(4.57gm). m.p.195oC, (C35H29N7S; Found : C, 72.51%; H, 5.04%; N, 16.91%
; Required : 72.41%; H, 5.01%; N, 16.83%).
TLC solvent system : Acetone : Benzene (2.5 : 7.5).
Similarly other aminopyrimidines were prepared. The physical data are
recorded in Table No. 8
[D] Antimicrobial activity of 6-Arylimino-7,N-aryl-2-amino-4-(1',N-
phenyl-3'-p-tolyl-pyrazol-4'-yl)-thiazolidino-(4,5-d)-pyrimidines
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
























8a C6H5- C33H25N7S 551 138 0.58 62 17.77 17.33
8b 2-OCH3-C6H4- C35H29N7O2S 611 160 0.67 59 16.03 16.07
8c 4-OCH3-C6H4- C35H29N7O2S 611 170 0.53 58 16.03 16.01
8d 2-NO2-C6H4- C33H23N9O4S 641 109 0.66 71 19.65 19.59
8e 3-NO2-C6H4- C33H23N9O4S 641 215 0.61 58 19.65 19.58
8f 4-NO2-C6H4- C33H23N9O4S 641 145 0.49 60 19.65 19.68
8g 4-Cl-C6H4- C33H23Cl2N7S 620 135 0.51 64 15.80 15.84
8h 4-COOH-C6H4- C35H25N7O4S 639 173 0.62 69 15.33 15.37
8i 3-CH3-C6H4- C35H29N7S 579 180 0.59 72 16.91 16.87
8j 4-CH3-C6H4- C35H29N7S 579 195 0.48 79 16.91 16.83
8k 3-Cl,4-F--C6H3- C33H21N7SF2Cl2 656 128 0.55 57 14.93 14.85
8l 2,5-(Cl)2-C6H3- C33H21N7SCl4 689 173 0.69 60 14.22 14.18
































B.mega 15 16 19 17 17 20 14 19 21 11 22 16 23 22
S.aureus 15 14 14 15 11 12 15 13 16 17 20 21 22 23
P.vulgaris 14 11 13 13 12 13 14 14 18 15 17 14 15 18
E.coli 13 15 14 15 17 16 13 20 14 19 13 21 21 21
A.niger 14 14 15 11 18 21 14 17 16 22 17 18 0 0





COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-V
Section - I : Antimicrobial activity of 6-Arylimino-7,N-aryl-2-Amino-4-(1',N-phenyl-3'-p-tolyl-pyrazol-4'-yl)
thiazolidino-[4,5-d]-pyrimidines
8f (20) 8k (20) 8i (18) 8h (20) 8f (21)
8i (21) 8l (21) 8k (17) 8l (21) 8j (22)
8k (22)
Ampicillin 23 22 15 21 -
Amoxicillin 22 23 18 21 -
Norfloxacin 24 17 17 23 -
Penicillin 25 24 20 19 -
Greseofulvin - - - - 25
B. mega S. aureus P. vulgaris E. coli A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity






Nitriles are reported to possess various therapeutic activities, but due to
their high toxicity, they have low therapeutic importance. The term "Nitrile"
was first introduced by Febung387 in 1844. The first synthesis of nitrile has been
reported by Wohler and Liebig388 in 1832 and Poleuze389 in 1834. They are
very much useful as intermediates for various products such as acrylonitrile for
plastic, synthetic rubber and fibers, phthalonitrile for dye stuff.
SYNTHETIC ASPECT :
D. Mowry390 reviewed various methods of preparation of nitrile. Few recent
methods are as mentioned below.
1. From halides using NaCN; Al2O3
391
2. From alkylholides using KCN tetraalkyl ammonium salt392 and water in
trace.
3. The pyrolysis of Schiff's base393.
4. Mohanakrishna A. K. and co-worker394 have synthesised nitrile derivatives.
MECHANISM :
























They shows various therapeutic activities, which are described as under.
1. Antihypertensive395







Cardenalide nitrile showed moderate biological activity in rats.403 Nitriles,
with fused pyridine ring were reported as ulser inhibitor404. Kobayashi Shigco
et al.405 have synthesised new derivatives of nitriles. M. C. Dougal406 have
synthesised nitriles and studied their pharmacological activities.
Lai Hai Kiong and co-workers407 have reported nitriles showing fungicidal
activity.
Valmajer Juliya et al.408 synthesied some new nitriles and reported them
as anticonvulsant agent. Shibata Yasushi and co-workers409 have synthesised
nitrile derivatives associated with insecticides. Nosyrava et al.410 have prepared
novel nitriles which have been shown to possess muscle relaxant activity. Yagihara
and co-workers411 have prepared nitriles which possess antimicrobial and
antiinflammatory activity.
Parlo Sanna et al.412 have synthesised nitriles (I) and screened for their
antitubercular activity. Iwanowicz E. J. et al.413 have prepared nitriles (II) and
found to preventing and treating IMPDH associated disorders, such as transplant
rejection and autoimmune disease.
126Nitriles...
Collin Xavier and co-workers414 have synthesised antifungal acetonitriles.
Bhatnagar Neerja et al.415 have synthesised nitriles as inhibitors of Cathepsin
K. Bernard M. et al.416 have synthesised nitriles as thromboxane receptor
antagonists.  Alwal K.S et al .417 have prepared nit i les as inhibitors of
mitochondrial F1F0 ATPase. Recently, Mura Kami Hiroshi et al.
418 have
synthesised some new nitriles and screened for their pesticidal and marin
antifouling activity.
CONTRIBUTION FROM OUR LABORATORY :
F. M. Bharmal, D. J. Kaneria and H. H. Parekh419 have synthesised newer
acetonitriles bearing quinaline moiety and tested as antimicrobial agents. (III)
Looking to the interesting properties of nitriles, we have synthesised some
new nitriles, which have been described as under.
























SYNTHESIS AND THERAPEUTIC EVALUATION OF-α-ARYLAMIN0-
1,N-PHENYL-3-p-TOLYL-PYRAZOL-4-YL-ACETONITRILES
In view of therapeutic activities of nitriles it was contemplated to synthesise
some new nitriles in search of agents possessing higher biological activity. Nitriles
of type (IX) have been synthesised by the reaction of 1,N-phenyl-3-p-tolyl-4-
formyl-pyrazole with different aromatic amines by the presence of potassium
cyanide and glacial acetic acid at 0-5oC.
The constitution of the systhesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and mass spectrometry also. In mass spectrometry the m/z value indicate the
molecular weight i.e., when R=4-methoxy phenyl, molecular weight = 394, m/z
= 395 (m+1).
The products have been screened for their in vitro biological assay
like antimicrobial activity towards Gram positive and Gram negative bacterial
strains and antifungal activity towards Aspergillus niger at a concentration of
40 µg/ml. The biological activities of the synthesised compounds were compared
with standard drugs, recorded on Page No.136. The details have been cited in













R = ArylType (IX)
128
IR SPECTRAL STUDY OF α-p-TOLYLAMINO-1,N-PHENYL-3-p-TOLYL-PYRAZOL-4-YL-
ACETONITRILE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2912 2975-2950 614
-CH3 C – H str.(sym.) 2856 2880-2860 "
C – H i.p. (def.) 1452 1470-1435 "
C-H o.o.p. (def.) 1380 1395-1370 "
Aromatic C – H str. 3020 3090-3030 615
C = C str. 1552 1585-1570 "
1500 1520-1480 "
C – H i.p. (def.) 1124 1125-1090 "
1056 1070-1000 "
C–H o.o.p. (def.) 810 835-810 "
Pyrazole C = N str. 1596 1610-1590 616
moiety C – N str. 1215 1230-1220 "
Nitrile C=N str. 2229 2240-2220 618








PMR SPECTRAL STUDY OF α-p-ANISYLAMINO-1,N-PHENYL-3-p-TOLYL-PYRAZOL-4-
YL-ACETONITRILE
Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1. 2.37 3H singlet Ar-CH3 -
2. 3.78 3H singlet Ar-OCH3 -
3. 5.31 1H singlet -CHk (nitrile) -
4. 6.75-6.78 2H doublet Ar-H g,g' Jgf=9
5. 6.85-6.88 2H doublet Ar-H f,f' Jfg = 9
6. 7.21-7.24 2H doublet Ar-H (a, e) Jab & Jed=8.1
7. 7.30-7.35 1H triplet Ar-Hc -
8. 7.45-7.50 2H triplet Ar-H (b,d) -
9. 7.66-7.69 2H doublet Ar-H j,j' Jji=7.8
10. 7.74-7.76 2H doublet Ar-H i,i' Jij=7.8







































































































































SYNTHESIS AND THERAPEUTIC EVALUATION OF α-ARYLAMINO-
1,N-PHENYL-3-p-TOLYL-PYRAZOL-4-YL-ACETONITRILES
[A] Synthesis of N-Phenylamine-α-methyl-α-p-tolyl azomethine
See, Part-I, Section-I (B)
[B] Synthesis of 1,N-Phenyl-3-p-tolyl-4-formyl-pyrazole
See, Part-I, Section-I (B)
[C] Synthesis of α-p-Anisylamino-1,N-phenyl-3-p-tolyl pyrazol-4-yl-
acetonitrile
1,N-Phenyl-3-tolyl-4-formyl-pyrazole (2.62 gm, 0.01M) dissolved in ethanol
(25 ml) was added to potassium cyanide (0.64 gm, 0.01M) disolved in water (5
ml) followed by glacial acetic acid (5 ml). The contents were then stirred for 5
minutes to form cyanohydrin at 0oC. p-Anisidine (1.23 gm, 0.01M) dissolved in
methanol was added to the reaction mixture, contents were kept at room
temperature for 24 hrs. and poured into ice. The solid product was crystallized
from ethanol. Yield,  75% (2.95 gm), m.p. 109oC. (C25H22ON4 ; Found : C,
76.12%; H, 5.62%; N, 14.20%; Required : C, 76.9%; H, 5.58%; N, 14.15%).
TLC solvent system : Acetone : Benzene (2:8).
Similarly other nitriles were prepared. The physical data are recorded in
Table No. 9.
[D] Antimicrobial activity of α-Arylamino-1,N-phenyl-3-p-tolyl-pyrazol-
4-yl-acetonitriles
Antimicrobial testing was carried out as described in Part-I, Section-I (D).























9a C6H5- C24H20N4 364 190 0.47 61 15.37 15.32
9b 3-CH3-C6H4- C25H22N4 378 210 0.47 65 14.80 14.72
9c 4-CH3-C6H4- C25H22N4 378 185 0.49 60 14.80 14.74
9d 2,3-(CH3)2-C6H3- C26H24N4 392 173 0.51 63 14.27 14.18
9e 2-OCH3-C6H4- C25H22ON4 394 128 0.58 59 14.20 14.13
9f 4-OCH3-C6H4- C25H22ON4 394 109 0.60 75 14.20 14.15
9g 3-Cl-C6H4- C24H19N4Cl 398.5 153 0.61 61 14.05 14.01
9h 4-Cl-C6H4- C24H19N4Cl 398.5 165 0.62 66 14.05 14.03
9i 2,5(Cl)2-C6H3- C24H18N4Cl2 433 173 0.65 59 12.93 12.89
9j 2,6-(Cl)2-C6H3- C24H18N4Cl2 433 143 0.51 66 12.93 13.00
9k 2-NO2-C6H4- C24H19N5O2 409 168 0.57 63 17.10 17.01
9l 3-NO2-C6H3- C24H19N5O2 409 173 0.53 58 17.10 17.06
9m 4-NO2-C6H4- C24H19N5O2- 409 104 0.49 55 17.10 17.13
































B.mega 18 20 16 17 16 14 16 15 17 19 18 17 14 23 22 24
S.aureus 15 17 14 18 13 12 13 15 14 16 17 12 15 22 23 17
P.vulgaris 17 15 18 13 19 15 12 13 13 15 14 11 12 15 18 17
E.coli 18 16 14 13 14 12 13 12 13 14 15 14 18 21 21 23
A.niger 12 14 16 13 11 17 17 18 22 19 15 20 21 0 0 0








COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-VI
Section - I : Antimicrobial activity of α-Arylimino-1,N-phenyl-3-p-tolyl-4-yl-acetonitriles
9b (20) 9b (17) 9c (18) 9a (18) 9i (20)
9j (19) 9d (18) 9e (18) 9m (18) 9l (20)
9k (17) 9m (21)
Ampicillin 23 22 15 21 -
Amoxicillin 22 23 18 21 -
Norfloxacin 24 17 17 23 -
Penicillin 25 24 20 19 -
Greseofulvin - - - - 25
B. mega S. aureus P. vulgaris E. coli A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity






Imidazolinone, a five membered heterocycle having 2-nitrogen atoms at
the 1 and 3-positions and C=O group at following positions : 2-oxo-imidazoline
(I), 4-oxo-imidazoline (II), 5-oxo-imidazoline (III).
The discovery of the 2-substituted-5-imidazolines dates back to the year
1888, when A. W. Hoffmann420 for the first time discovered 5-oxo-imidazoline
by heating N'-diacetylethylene diamine in a stream of dry hydrogen chloride.
More over the some compound was prepared by A. Ladenburg421 by the fusion
of two equivalents of sodium acetate with one equivalent of ethylene diamine
dihydrochloride.
SYNTHETIC ASPECT :
Various methods have been reported for the synthesis of imidazolinones in
literature422 Aminolysis of oxazolone with amine leads to the formation of
imidazolinones which have been reported in literature.423
1. A. Saxena et al.424 have synthesised new imidazolinones in pyridine.
2. Allimony et al.425 have synthesised (II) new imidazolinone derivatives by
conventional method.





























Azalactone reacts with variety of compounds such as water, alcohols, amines
and hydrogen halides. Amides of α-acylamino acrylic acids obtained from the
condensat ion of  aza lac tone and pr imary amine can be conver ted to
imidazolinones as shown under.
The ring closer can be effected under a variety of conditions. Substituted
anilides have been converted to imidazolinone derivatives by the action of
POCl3.
THERAPEUTIC IMPORTANCE
Naphazoline hydrochloride, xylometazoline hydrochloride etc. are various
imidazolinone derivatives which have been used as adrenergic stimulants and
tolazol ine and phenotolamine as adrenergic  b locking agents .  Var ious
imidazolinones are known to exhibit a broad spectrum of biological activities
such as.
1. Antitubercular427






































K. Awasthi et al.453 have synthesised some new imidazolinone derivatives
and reported their antimicrobial activity.
Farmshow Christopher Geoffrey et al.454 and Pilkington et al.455 have
synthesised and studied antifungal activity of imidazolinones. L. Joseph Peter
and co-woreker456 have prepared substituted imidazolinones which inhibited
the abnormal cell growth in human body. Stefama Laufer and co-worker457 have
isolated imidazolines from different methods and tested for the treatment of
cytokine release. Battistina et al. have demonstrated some novel imidazolines to
possess insecticidal activity. Imidazoline derivatives have been prepared by
Declera-Arthur and co-worker458 showing anti HIV activity. Ding, Ming-Wu et
al.459 have prepared novel imidazolines and reported their antifungal activity.
Kalhe Vishnu et al.460 have reported anti-AIDS, antibacterial and fungicidal
activity of 5-oxo-imidazolines. B. R. Shah and co-worker461 have prepared some
new imidazolines and reported anticancer and anti HIV activity.
V. Akyoshi et al.462 have prepared some new imidazolinone derivatives
and reported their herbicidal activity. Agrochemical activity of imidazolinones
have been reported by Bascou and co-workers.463
139Imidazolinones...
Rama Sharma and co-workers464 have reported antimicrobial activity of 5-
oxo-imidazolines.
CONTRIBUTION FROM OUR LABORATORY
Parikh et al.465 have synthesised imidazolinones bearing thiazole as
moderately active bactericidal and fungicidal H. H. Parekh et al.466 have
elaborated better activity for some imidazolinones with activated benzylidene
group at 5-position.
Recently, Dr. H. H. Parekh et al.467 suggested imidazolinones as a
antitubercular,  anticancer (IV).
H. H. Parekh and co-workers have synthesised imidazolinone derivatives
having isoniazide468 and 5-triazine469 moiety. Imidazolinones bearing
aminobenzylamino470, chlormphenical471 and phthalazine472 moiety at 1-
position have been demonstrated as a antimicrobial agents by A. R. Parikh and
co-workers.
A. R. Parikh et al. have synthesised imidazolinones bearing phthalazine473
2-base of chlormphenical,474 moiety at one position which were evaluated for
their antimicrobial activity. Parikh et al.475 have reported 4-(4'-arylidene-2'-
phenyl-5'-oxo-imidazolin-1'-yl)-benzophenone which were screened for their
antimicrobial activity. Biplabde et al.476 have reported some new 5-oxo-

















More, over A. R. Parikh, H. H. Parekh and co-workers have synthesised the
newer 5-oxo-imidazolines477-483 with different variety of activities.
Moreover Yoneda Naato et al.484 have synthesised imidazolinones as
antihypertensive agent. R. C. Dage et al.485 have synthesised cardiotonic
imidazolinones. Armando Rossello et al.486 have synthesised imidazolones as
antifungal agent. Cooper A. B. and co-workers487 have found that imidazolones
are inhibitors of farnesyl protein transferase. Machii Dalsuke et al.488 have
synthesised new imidazolones as a telomerase inhibitors and antitumor agents.
Jean M. R.  e t  a l .489 have synthes ised imidazol inones and tes ted as
antileishmanial agent.
Chafiq Hamdouchi et al.490 have synthesised imidazolinones and screened
for their potent and broad spectrum activity. Irene M. L. et al.491 have synthesised
imidazolinones and tested as antireteroviral activity.
Xu Zhi-Feng et al.492 have synthesised imidazolinones as biological agent.
With a view to getting better therapeutic agent, it was contemplated to
synthesise imidazolinones to enhance the overall activity of resulting compounds
which have been described as under.






SYNTHESIS AND THERAPEUTIC EVALUATION OF 1,N-ARYL-2-ALKYL/
ARYL-4- (1 ' ,N-PHENYL-3 ' -p -TOLYL-4 ' -PYRAZOLYL-METHINO)-
IMIDAZOLIN-5-ONES
Imidazolinones represent one of the most active classes of compounds having
a wide spectrum of biological activities with an aim to getting better therapeutic
agent. The preparation of 5-oxo-imidazolines of type (X) have been undertaken
by the condensation of azalactone with different aromatic amines as shown in
reaction scheme.
The constitution of the systhesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry. In mass spectrometry the m/z value
indicate the molecular weight i.e. when R1 & R2=phenyl, molecular weight=480,
m/z=480(m).
The products have been screened for their in vitro biological assay
like antimicrobial activity towards Gram positive and Gram negative bacterial
strains and antifungal activity towards Aspergillus niger at a concentration of
40 µg/ml. The biological activities of the synthesised compounds were compared
with standard drugs, recorded on Page No.136. The details have been cited in















































Type (X) R1 = Aryl
R2 = Alkyl/ Aryl
143
IR SPECTRAL STUDY OF 1,N-p-CHLROPHENYL-2-4-(1',N-PHENYL-3'-p-TOLYL-4'-
PYRAZOLYL METHINE)-IMIDAZOLIN-5-ONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2923 2975-2950 614
-CH3 C – H str.(sym.) 2833 2880-2860 "
C – H i.p. (def.) 1442 1470-1435 "
C-H o.o.p. (def.) 1365 1395-1370 "
Aromatic C – H str. 2999 3090-3030 615
C = C str. 1504 1520-1480 "
C – H i.p. (def.) 1105 1125-1090 "
1031 1070-1000 "
C–H o.o.p. (def.) 829 835-810 "
Pyrazole C = N str. 1598 1610-1590 616
moiety C – N str. 1245 1230-1220 "
Imidazolinone C=O str. 1714 1760-1655 614
ring C=N str. 1633 1650-1580 "
C–N str. 1245 1260-1220 "
C=C str. 2923 2950-2850 "










PMR SPECTRAL STUDY OF 1,N-PHENYL-2-METHYL-4-(1',N-PHENYL-3'-p-TOLYL-
4'-PYRAZOLYLMETHINE)-IMIDAZOLIN-5-ONE
Internal Standard : TMS; Solvent :CDCl3 : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 2.26 3H singlet Ar-CH3 -
2. 2.46 3H singlet Ar-CH3 -
3. 7.17-7.22 1H triplet Ar-Hc -
4. 7.35-7.38 3H doublet Ar-H g,g' & n Jgf=8.1
5. 7.40-7.46 2H triplet Ar-H (b, d) -
6. 7.48-7.49 2H doublet Ar-H (a, e) Jae & Jed=3
7. 7.50-7.53 2H doublet l,p, Jpo & Jlm=7.8
8. 7.56-7.59 2H doublet Ar-H f,f' Jfg=8.1
9. 7.90-7.93 2H doublet Ar-H (n, o) Jml & Jop=7.8
10. 7.95 1H singlet Hk -




















































































































































SYNTHESIS AND THERAPEUTIC EVALUATION OF 1,N-ARYL-2-
ALKYL/ARYL-4-(1',N-PHENYL-3'-p-TOLYL-4'-PYRAZOLYLMETHINO)-
IMIDAZOLIN-5-ONES
[A] Synthesis of 1,N-Phenyl-3-p-tolyl-4-formyl-pyrazole
See, Part-I, Section-I (B)
[B] Synthesis of 2-Methyl-4-(1' .N-phenyl-3 ' -p-tolyl-4 ' -pyrazolyl
methino)-oxazolin-5-one
A mixture of 1,N-phenyl-3-p-tolyl-4-formyl pyrazole (6.55 gm, 0.025 M),
acetic anhydride (7.6 ml, 0.075 mol) and sodium acetate (2.0 gm) was heated on
a waterbath for 4 hrs. Resulting mass was poured into ice cold water, filtered and
crystallised from DMF. Yield, 66%, m.p. 143oC, (C20H15N3O2; Found :
C,72.94%; H,4.59%; N, 12.76%; Required : C, 72.92%; H, 4.61%; N, 12.73%).
TLC solvent system : Ethyleacetate : Hexane (2 : 8).
[C] Synthesis of 1,N-Phenyl-2-methyl-4-(1',N-phenyl-3'-p-tolyl-4'-
pyrazolylmethino)-imidazolin-5-one
A mixutre of 2-Methyl-4-(1',N-phenyl-3'-p-tolyl-4'-pyrazolylmethino)-
oxazolin-5-one. (3.41 gm, 0.01 M) and aniline (0.93 g, 0.01M) in dry pyridine
(20 ml) was refluxed for 12 hrs. in oil bath. Resulting mass was poured into
crushed ice and neutralised with HCl, filtered and crystallized from dioxan. Yield,
69% (2.88 gm), m.p. 108oC, (C33H26N4O ; Found : C, 77.49%; H, 5.30%; N,
13.39%; Required : C, 77.46%; H, 5.27%; N, 13.31%).
TLC solvent system : Acetone : Benzene (1.5 : 8.5).
Similarly, other imidazolin-5-ones have been prepared. The physical
constants are recorded in Table No. 10.
148
[D] Antimicrobial activity of 1,N-Aryl-2-alkyl/aryl-4-(1',N-phenyl-3'-p-
tolyl-4'-pyrazolylmethino)-imidazolin-5-ones
Antimicrobial activity was carried out as described in Part-I, Section-I (D).






















10a -C6H5 -CH3 C21H22N4O 418 108 0.63 69 13.39 13.31
10b 4-Cl-C6N4 -CH3 C27H21N4OCl 452.5 135 0.59 52 12.37 12.33
10c 4-NO2C6H4 -CH3 C27H21N5O3 463 185 0.55 66 15.11 15.08
10d -C6H5 -C6H5 C32H24N4O 480 230 0.56 62 11.66 11.62
10e 2-CH3-C6H4 -C6H5 C33H26N4O 494 185 0.48 58 11.33 11.27
10f 4-CH3-C6H4 -C6H5 C33H26N4O 494 103 0.50 64 11.33 11.28
10g 2-OCH3C6H4 -C6H5 C33H26N4O2 510 135 0.55 68 10.97 10.91
10h 4-OCH3-C6H4 -C6H5 C33H26N4O2 510 127 0.44 70 10.97 10.93
10i 4-F-C6H4 -C6H5 C32H23N4OF 498 164 0.56 71 11.24 11.19
10j 4-Cl-C6H4 -C6H5 C32H23N4OCl 514.5 178 0.48 63 10.88 10.83
10k 3,4-(Cl)2C6H3 -C6H5 C32H22N4OCl2 549 139 0.50 65 10.20 10.17
10l 2,6(Cl)2-C6H3 -C6H5 C32H22N4OCl2 549 164 0.69 57 10.20 10.14




































B.mega 17 16 14 21 20 13 15 22 20 18 12 15 23 22 24
S.aureus 15 15 19 20 19 14 20 17 18 22 16 15 22 23 17
P.vulgaris 18 20 14 17 18 13 12 10 15 17 16 14 15 18 17
E.coli 17 14 20 18 15 18 13 12 10 11 14 15 21 21 23
A.niger 13 17 18 20 22 14 20 13 15 11 10 14 0 0 0







COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-VII
Section - I : Antimicrobial activity of 1,N-Aryl-2-alkyl/aryl-4-(1',N-phenyl-3-p-tolyl-4'-pyrazolylmethine)-
imidazoline-5-ones
10d (21) 10d (20) 10b (20) 10c (20) 10d (20)
10e (20) 10g (20) 10e (18) 10d (18) 10c (22)
10h (22) 10j (22) 10f (18) 10g (20)
10i (20)
Ampicillin 23 22 15 21 -
Amoxicillin 22 23 18 21 -
Norfloxacin 24 17 17 23 -
Penicillin 25 24 20 19 -
Greseofulvin - - - - 25
B. mega S. aureus P. vulgaris E. coli A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity






The group of compounds containing  quinoline moiety are a prominent
structural feature in a variety of natural products like angostural alkalaids
echipsine493 as well as in other compounds of medicinal interest and have
attracted attention for their biological activities. The chemistry of quinoline and
its derivatives, have been the centre of attention for a longtime. As indicated the
quinoline contains a phenyl ring fused to pyridine ring, hence also designed as
benzopyridine. R. H. Manske494 and F-w. Bergstrom495 have done excellent
work on quinoline and its derivatives.
SYNTHETIC ASPECT :
Different methods used for the synthesis of quinoline and its derivatives
reported in literature496-498 are as under.
1. Meth-Cohn and co-workers499 used Vilsmeier-Haack reagent with POCl3
as solvent and prepared quinoline derivatives.
2. Tetrahydro quinoline derivatives have been prepared by M. Lancaster and
D. J. Smith.500
MECHANISM
In th 1st step hydroxy group is replaced by chlorine, wich is possible by
lone pair of electron of halogen atom. In the second step Vilsmeir-Haack reagent








This intermediate upon treatment by POCl3 leads to the quinoline molecule.
THERAPEUTIC IMPORTANCE
There  are  some quino l ine  der iva t ives  repor ted to  possess  to








































































Considerable interest has been aroused in the chemistry of quinoline due














quinolin-3-yl]-1,3,4-oxadiazoles show antihypertensive activity519 Shoda,
Takashi et al.520 have prepared quinoline derivatives of and screened for
antiarthritis and antiinflammatory agents.
Mastsumato and co-workers521 have prepared 4-keto quinoline derivatives














R1 = H, R2 = Halo
R3 = H, Me
X = O, N
Nichols and co-workers522 synthesised quinoline derivatives (III) having
anticonvulsant activity. Faizi et al.523 have evaluated 8-hydroxyquinoline
derivatives as an analgesic while Hamouly et al.524 have reported quinoline
derivatives as an antiallergic. Oku et al.525 have synthesised 2-methylquinoline-
8-ether derivatives and reported its antagonist activity.
Watanobe et al.526 have reported quinoline derivatives as cardiovascular
agent. Starke carl527 have prepared 4-anilino-8-(alkyl/thioalkoxy) quinoline
derivatives as gastric acid secretion inhibitor. Strony Henry Lee528 reported
herbicidal activity of (IV).
George Y et al.529 have synthesised some new substituted 2-quinoline
caroboxalde thiosemicarbazone and displayed it's antileishmarial activity.
Quinoline sulfide derivatives have been reported as selective antibacterial agent
for Helicobacter Pylorr530. Yuan Jun et al.531 have synthesised some new
quinoline derivatives and screened as GABA receptors.
Thus the important role displayed by quinoline and its derivatives for various
therapeutic and biological activities prompted us to synthesise some chalcone,
cyanopyridine and azomethine. Derivatives, in order to achieve better drug
potential.
[B] STUDIES ON CHLOROQUINOLINE DERIVATIVES
PART-VIII : STUDIES ON CYANOPYRIDINES
PART-IX : STUDIES ON AZOMETHINES









R1 = R2 = R3 = H, Halo, NO2





Pyridines is the parent of the series of compounds that is important in
pharmaceutical, agriculture and industrial chemistry. Among a wide range of
pyridines, -3-cyanopyridines acquired a special attention due to their wide range
of therapeutic activities. Most derivatives are prepared by manipulation of
pyridine and its simple homologues in a manner similar to chemistry of the
benzenoid chemistry. However the simple pyridine compounds are prepared by
the cyclisation of aliphatic raw materials.
SYNTHETIC ASPECT :
Preparation of 3-cyanopyridines have been cited in literature532-537 with
different methods.
1. Samour and co-worker538 prepared substituted cyanopyridines by the
condensation of chalcones with malononitrile in presence of ammonium
acetate.
MECHANISM :
The reaction proceeds through conjugate addition of active methylene














The extensive use of cyanopyridine derivatives have been established in











S. S. Verma et al.548 and M. D. Ankhiwala549 have synthesised 2-amino-
3-cyano-2,6-disubstituted pyrimidines and studied their biological activities. The
insecticidal activity of cyanopyridines have been screened by Y. Sasaki550 et al.
Umed Ten et al.551 have prepared cyanopyridines as agrochemical fungicides.
Parekh et al.552-554 have synthesised the series of cyanopyridines and
postulated them as antimicrobials. A. R. Parikh et al.555-557 have prepared some
new cyanopyridines & studied their antimicrobial activity. The oxide activator













































prepared cyanopyridine derivatives which inhibit cerebral edema and delayed
neuron death. Hence, they are useful as cerebral edema inhibitors or
cerebrovascular disorder remedies.
El-Nabawia et al.560 have prepared new 2-amino-3-cyano pyridine
derivatives (II) and studied their antimicrobial activity. S. Guru et al.561 have
synthesised various cyanopyridyl derivatives (III) and documented their multiple
biological activities.
Several co-workers have prepared some new cyanopyridine derivatives and
reported their cholinesterase inhibitors,562 antihistaminic and antiallergic,563
adernergic,564 herbicidal,565 antiinflammatory566 &  insecticidal567 activities.
Some new 3-cyanopyridine derivatives synthesised by Hammama A. & co-
workers568 showed anticancer and anti HIV-I activity. Abdallah N. et al.569 have
synthes i sed cyanopyr id ine  der iva t ives  which showed ana lges ic  and
antiinflammatory activity.
The synthesis of cyanopyridines are of current interest owing to their
enormous occurence in biologically active derivaties. Hence, considerable
attention has been focused on the study of efficient & pharamaceutical important














Moreover Miertus et al.570 synthesised 2-formyl pyridine thiosemicarbazone
as a carcinostatic agent. Adriano Afonso et al.571 have found that cyanopyridines
are Fernesyl protein tranferase inhibitors. Hussain et al.572 have synthesised
cyanopyridines as antimicrobial agent. Wu Wenxue et al.573 have synthesised
cyanopyridines as histamine H3 antagonists. Saudi Manal N. S. et al.
574 have
found that cyanopyridines have fascialicidal property. Harada Hironori et al.575
have prepared cyanopyridines and screened for their large conductance calcium-
activated potassium channel opener activity.
Thus, diverse biological activities have been encountered in compounds
containing cyanopyridine ring system. To further assess the potential of such
type of compounds, study of cyanopyridines have been carried out as under.
CONTRIBUTION FROM OUR LABORATORY
A. R. Parikh, H. H. Parekh et al. have synthesised cyanopyridines with
versatile biological activities576-583 like antimicrobial, antitubarcular and
anticancer.
SECTION-I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
1-ARYL-3-(2'-CHLORO-6'-METHOXY-QUINOLIN-3'-
YL)-2-PROPENE-1-ONES





SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-ARYL-3-(2'-
CHLORO-6'-METHOXY-QUINOLIN-3'-YL)-2-PROPENE-1-ONES
Recently, much interest has been focused on the synthesis and biodynamic
activities of chalcones. With a view to obtaining compounds having better
therapeutic activity, we have synthesised chalcone of type (XI) by condensing
2-chloro-6-methoxy-3-quinolinecarboxaldehyde with various aromatic ketones.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. In mass spectrometry
m/z value indicate the molecular weight, i.e. when R=4-methylphenyl, molecular
weight=337.5 m/z=338 (m).
All the compounds have been screend for their invitro biological activity
like antitubercular activity towards a strain of Mycobacterum tubarculosis
H37 Rv at  a concontration of 6.25 µg/ ml using Rifampin as a standard drug,
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concelteation of 40 µg/
ml. The biological activity of the synthesised compounds have been compared
with standard drugs. Some compounds have been found to have good and
equivalent activity as compared to the known antibiotics recorded on Page







































Type (XI) R = Aryl
162
IR SPECTRAL STUDY OF 1-p-TOLYL-3'-(2'-CHLORO-6'-METHOXY QUINOLIN-3'-YL)-
2-PROPENE-1-ONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2923 2975-2950 614
-CH3 C – H str.(sym.) 2852 2880-2860 "
C – H i.p. (def.) 1428 1470-1435 "
C-H o.o.p. (def.) 1369 1395-1370 "
Aromatic C – H str. 3064 3090-3030 615
C = C str. 1480 1520-1480 "
C – H i.p. (def.) 1010 1070-1000 "
C–H o.o.p. (def.) 825 835-810 "
Quinoline C = N str. 1604 1612-1593 616
nucleus C – Cl. str. 732 750-700 "
α−β-unsatureted C=O str. 1658 1700-1640 617
Ketone –CH=CH– str. 1604 1644-1618 "
C–H wag. 972 980-965 618
Ether C–O–C str. (asym.) 1263 1260-1220 616







PMR SPECTRAL STUDY OF 1-p-TOLYL-3-(2'-CHLORO-6'-METHOXY-QUINOLIN-3'-
YL)-2-PROPENE-1-ONE
Internal Standard : TMS; Solvent : CDCl3: Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 2.45 3H singlet Ar-CH3 -
2. 3.95 3H singlet Ar-OCH3 -
3. 7.12-7.13 1H doublet Ar-Hf Jfe=8.7
4. 7.31-7.34 2H doublet Ar-H g,g' Jgh=8.4
5. 7.39-7.43 1H d,doublet Ar-He -
6. 7.56-7.61 1H doublet -CHB JBA=15.6
7. 7.87-7.90 1H doublet Ar-Hd Jde=10.8
8. 7.95-7.98 2H doublet Ar-H h, h' Jhg=8.4
9. 8.14-8.19 1H doublet -CHA JAB=15.6




































































































SYNTHESIS AND THERAPEUTIC EVALUATION OF 1-ARYL-3-(2'-
CHLORO-6'-METHOXY QUINOLIN-3'-YL)-2-PROPENE-1-ONES
[A] Preparation of N-Acetyl-p-anisidine
A mixture of p-Anisidine (1.23gm, 0.01M) and acetic anhydride (1.12gm,
0.011M) in acidic medium was refluxed for half an hour. The resulting mixture
was poured into crushed ice and crystallised from hot water. Yield, 66% (1.1gm),
m.p. 167oC, (C9H11NO2 ; C,65.44%; H,6.71%; N, 8.48%; Fond : C,65.41%; H,
6.68%; N, 8.44%). TLC solvent system : Acetone : Benzene (2:8).
[B] Preparation of 2-Chloro-6-methoxy-3-quinolincarboxaldehyde
Dimethylformamide (9.13 gm, 0.125M) was cooled to 0oC in a flask
equipped with a drying tube and phosphouras oxychloride (53.7 gm, 0.35M)
was added dropwise with stirring. To this solution was added the N-acetyl-p-
anisidine (0.05 M) and after 15 min. The solution was heated under reflux for
15.5 hrs. at 75oC. The reaction mixture was poured into ice water (300.0 ml) and
stirred for 30 mins. at 10oC filtered, washed with water, dried, and crystallized
from ethyl acetate. Yield, 52% (1.15 gm), m.p. 135oC, (C11H8NClO2 ;
Found: C, 59.59%; H, 3.61%; N, 6.28%; Requi: C, 59.61%; H, 3.64%; N, 6.32%).
TLC solvent system : Acetone : Benzene (1.5:8.5).
[C] Preparation of 1-p-Tolyl-3-(2'-chloro-6'-methoxy quinolin-3'-yl)-2-
propene-1-one
p-Methylacetophenone (1.34gm, 0.01m) in ethanol (95%, 10 ml) was added
to the mixture of 2-chloro-6-methoxy-3-quinolincarboxaldehyde (2.20 gm, 0.01
M), ethanol (95%, 25ml), aqueous sodium hydroxide (40%) (just to alkaline)
and stirred for 24hrs. The contents were poured into crushed ice and isolated by
acidification and recrystallized from ethanol.
167
Yield, 74% (2.49gm), m.p. 150oC, (C20H16NClO2 ; Found : C, 71.7%; H, 4.73%;
N, 4.12% ; Required : C, 71.11%; H, 4.77%; N, 4.15%)
TLC solvent system : Acetone : Benzene (1:9).
Similarly other 1-Aryl-3-(2'-chloro-6'-methoxy-quinolin-3'-yl)-2-propene-1-
ones were prepared. The physical constants are recorded in Table No. 11.
[D] Antimicrobial activity of 1-Aryl-3-(2'-chloro-6'-methoxy quinolin-
3'-yl)-2-propene-1-ones
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No.
11.
[E] Antitubercular activity of 1-Aryl-3-(2'-chloro-6'-methoxy-quinolin-
3'-yl)-2-propene-1-ones
The antitubercular screening of the compounds of type (XI) were carried
out by TAACF, the Southern Research Institute, U.S.A. as described in Part-I,
Section-I (D) and the percentage of inhibition data of the compounds are























11a C6H5- C19H14O2NCl 323.5 195 0.49 74 4.33 4.30
11b 4-Br-C6H4- C19H13O2NClBr 402.5 123 0.50 65 3.48 5.41
11c 4-Cl-C6H4- C19H13O2NCl2 358 187 0.62 58 3.91 3.86
11d 4-CH3-C6H4- C20H16O2NCl 337.5 150 0.61 74 4.15 4.12
11e 4-OCH3-C6H4- C20H16O3NCl 353.5 165 0.59 63 3.96 3.93
11f 2-OH-C6H4- C19H14O3NCl 339.7 150 0.48 54 4.12 4.08
11g 4-OH-C6H4- C19H14O3NCl 339.7 193 0.58 70 4.12 4.09
11h 4-NH2-C6H4- C19H15O2N2Cl 338.5 210 0.61 78 8.27 8.31
11i 3-NO2-C6H4- C19H13O4N2Cl 368.5 135 0.50 53 7.60 7.64
11j 4-NO2-C6H4- C19H13O4N2Cl 368.5 186 0.49 64 7.60 7.57
11k 2-C4H3S- C17H11O2NClS 328.5 139 0.68 58 4.25 4.21
11l 2-C4H3O- C17H11O3NCl 312.5 164 0.47 63 4.46 4.39
































B.mega 18 14 19 14 17 14 15 19 16 20 13 14 23 22 24
S.aureus 20 18 20 17 19 16 13 18 12 13 14 14 22 23 17
P.vulgaris 18 14 16 18 13 16 17 10 15 12 14 13 15 18 17
E.coli 13 17 18 17 14 20 15 18 17 16 22 19 21 21 23
A.niger 18 16 15 20 14 15 23 22 16 17 18 21 0 0 0







COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[B]
PART-VIII
Section - I : Antimicrobial activity of 1-Aryl-3-(2-chloro-6'-methoxy-quinolin-3'-yl)-2-propene-1-ones
11c (19) 11a (20) 11a (18) 11f (20) 11d (20)
11j (20) 11c (20) 11d (18) 11k (22) 11g (23)
11e (19) 11h (22)
11l (21)
Ampicillin 23 22 15 21 -
Amoxicillin 22 23 18 21 -
Norfloxacin 24 17 17 23 -
Penicillin 25 24 20 19 -
Greseofulvin - - - - 25
B. mega S. aureus P. vulgaris E. coli A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
171
172
TABLE NO.11a : DATA OF IN VITRO EVALUATION OF ANTITUBERCULAR ACTIVITY
TAACF, Southern Research Institute Dr. A. R. Parikh
Primary Assay Summary Report Saurashtra University
Sample Corp Where,R= Supplier Assay MTb MIC % comment
ID ID Strain µg/ml Inhib
162209 KB-1 C6H5- Sau.uni Alamar H37Rv >6.25 10
162210 KB-2 4-Br-C6H4- Sau.uni Alamar H37Rv >6.25 15  ''
162211 KB-3 4-Cl-C6H4- Sau.uni Alamar H37Rv >6.25 33  ''
162212 KB-4 4-CH3-C6H4- Sau.uni Alamar H37Rv >6.25 0  ''
162213 KB-5 4-OCH3-C6H4- Sau.uni Alamar H37Rv >6.25 0  ''
162214 KB-6 2-OH-C6H4- Sau.uni Alamar H37Rv >6.25 81  ''
162215 KB-7 4-OH-C6H4- Sau.uni Alamar H37Rv >6.25 0  ''
162216 KB-8 4-NH2-C6H4- Sau.uni Alamar H37Rv >6.25 17  ''
162217 KB-9 3-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 0  ''
162218 KB-10 4-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 11  ''
162219 KB-11 2-C4H3O- Sau.uni Alamar H37Rv >6.25 28  ''
162220 KB-12 2-C4H3S- Sau.uni Alamar H37Rv >6.25 -  ''
NIAID/ Southern Research institute/ GWL Hansen's Center/
Colorado state university proprietary information.
MIC Ri fampin
= 0.25µg/ml








SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-AMINO-3-
CYANO-4-(2 ' -CHLORO-6'-METHOXY QUINOLIN-3' -YL)-6-ARYL-
PYRIDINES
Cyanopyridines have been found to possess wide range of therapeutic
activities and of industrial importance. The synthesis of cyanopyridines of type
(XII) have been undertaken by condensation of chalcones of type (XI) with
malanonitrile as shown below.
The constitution of the systhesised products have been characterised using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and mass spectrometry. In mass spectrometry m/z value indicate the molecular
weight i.e. R=4-methoxyphenyl, molecular weight=416, m/z 117 (m+1).
All the compounds have been screend for their invitro biological activity
like antitubercular activity towards a strain of Mycobacterum tubarculosis
H37 Rv at  a concontration of 6.25 µg/ ml using Rifampin as a standard drug,
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concelteation of 40 µg/
ml. The biological activity of the synthesised compounds have been compared
with standard drugs. Some compounds have been found to have good and
equivalent activity as compared to the known antibiotics recorded on Page
No.182. The details have been cited in Part-I, Section-I(D).
















IR SPECTRAL STUDY OF 2-AMINO-3-CYANO-4-(2'-CHLORO-6'-METHOXY-QUINOLIN-
3'-YL)6--p-ANISYL-PYRIDINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2935 2975-2950 614
-CH3 C – H str.(sym.) 2837 2880-2860 "
C – H i.p. (def.) 1494 1470-1435 "
C-H o.o.p. (def.) 1371 1395-1370 "
Aromatic C – H str. 3020 3090-3020 615
C = C str. 1550 1585-1570 "
1494 1520-1480 "
C – H i.p. (def.) 1124 1125-1090 "
1055 1070-1000 "
C–H o.o.p. (def.) 831 835-810 "
Quinoline C = N str. 1600 1612-1593 614
nucleus C – Cl str. 781 800-700 "
Ether C–O–C str. (asym.) 1224 1260-1220 616
C–O–C str. (sym.) 1028 1075-1020 "
Pyridine N–H str. (-NH2) 3344 3350-3250 617
ring C=N str. 2214 2240-2120 "










PMR SPECTRAL STUDY OF 2-AMINO-3-CYANO-4-(2'-CHLORO-6'-METHOXY
QUINOLIN-3'-YL)-6-p-ANISYL-PYRIDINE
Internal Standard : TMS; Solvent : CDCl3 : DMSOd6: Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 3.88 3H singlet Ar-OCH3 -
2. 3.95 3H singlet Ar-OCH3 -
3. 6.97-7.00 2H doublet Ar-H g,g' Jgh=8.7
4. 7.14 1H singlet Ar-HA;
cyanopyridine ring -
5. 7.190-7.199 1H doublet Ar-Hf Jfe=2.7
6. 7.44-7.48 1H doublet Ar-He -
7. 7.94-7.96 1H doublet Ar-Hd Jde=9
8. 8.0-8.03 2H doublet Ar-H h, h' Jhg=8.7




















































































































SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-AMINO-3-
CYANO-4-(2 ' -CHLORO-6'-METHOXY QUINOLIN-3' -YL)-6-ARYL-
PYRIDINES
[A] Preparation of N-Acetyl-p-anisidine
See, Part-VIII, Section - I (A).
[B] Preparation of 2-Chloro-6-methoxy-3-quinolin-carboxaldehyde
See, Part-VIII, Section-I (B).
[C] Preparation of 1-Aryl-3-(2'-chloro-6'-methoxy quinolin-3'-yl)-2-
propene-1-ones
See, Part-VIII, Section-I (C).
[D] Preparation of 2-Amino-3-cyano-4-(2'-chloro-6'-methoxy quinolin-
3'-yl)-6-p-anisyl-pyridine
A mixture of 1-p-Anisyl-3-(2'-chloro-6'-methoxy quinolin-3'-yl)-2-propene-
1-one (3.53 gm, 0.01M), malononitrile (0.66 gm, 0.01M) and ammonium acetate
(6.61gm, 0.08M) dissolved in absolute alcohol (20 ml) was heated under reflux
for 8 hrs. The product was isolated and recrystallised from ethanol. Yield, 55%
(2.29gm), m.p. 114oC, (C23H17NHO2Cl ; Found : C, 66.25%; H, 4.8%; N, 13.39
%, Required : C, 66.27%; H, 4.11%; N, 13.44%).
TLC solvent system : Acetone : Benzene (3:7).
Similarly other 2-Amino-3-cyano-4-(2'-chloro-6'-methoxy quinolin-3'-yl)-6-
aryl-pyridines were prepared. The physical constants are recorded in Table No.
12.
178
[E] Antimicrobial activity of 2-Amino-3-cyano-4-(2'-chloro-6'-methoxy-
quinoline-3'-yl)-6-aryl-pyridines
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No.
12
[F] Antituberculor activity of 2-Amino-3-cyano-4-(2'-chloro-6'-methoxy
quinolin-3'-yl)-6-aryl-pyridines
The antitubercular screening of the compounds of type (XII), were carried
out by TAACF, the Southern Research Institute, U.S.A. as described in Part-I,
Section-I (D) and the percentage of inhibition data of the compounds are























12a C6H5- C22H15ON4Cl 386.5 175 0.43 75 14.48 14.43
12b 4-Br-C6H4- C22H14ON4ClBr 465.5 168 0.57 68 12.03 12.01
12c 4-Cl-C6H4- C22H14ON4Cl2 421 108 0.40 65 13.30 13.27
12d 4-CH3-C6H4- C23H17ON4Cl 400.5 135 0.47 70 13.98 13.87
12e 4-OCH3-C6H4- C23H17O2N4Cl 416.5 114 0.56 55 13.44 13.39
12f 2-OH-C6H4- C22H15O2N4Cl 402.5 109 0.69 58 13.91 13.89
12g 4-OH-C6H4- C22H15O2N4Cl 402.5 137 0.70 78 13.91 12.87
12h 4-NH2-C6H4- C22H16ON5Cl 491.5 201 0.57 61 17.43 17.38
12i 3-NO2-C6H4- C22H14ON5Cl 431.5 187 0.60 80 16.22 16.19
12j 4-NO2-C6H4- C22H14ON5Cl 431.5 164 0.59 63 16.22 16.23
12k 2-C4H3S- C20H13ON4SCl 392.5 153 0.57 59 14.26 14.21
12l 2-C4H3O- C20H13O2N4Cl 376.5 140 0.63 63 14.87 14.83
































B.mega 18 12 15 22 17 19 23 20 17 21 16 15 23 22 24
S.aureus 17 15 13 14 19 18 16 21 18 19 17 13 22 23 17
P.vulgaris 17 18 17 11 16 19 17 14 13 14 19 12 15 18 17
E.coli 15 17 18 14 19 14 13 17 14 19 20 16 21 21 23
A.niger 21 20 16 18 19 20 17 19 21 14 16 22 0 0 0







COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[B]
PART-VIII
Section - II : Antimicrobial activity of 2-Aimino-3-cyano-4-(2-chloro-6'-methoxy-quinolin-3'-yl)-6-aryl-
pyridines
12d (22) 12e (19) 12f (19) 12e (19) 12a (21)
12g (23) 12h (21) 12k (19) 12j (19) 12i (21)
12h (20) 12j (19) 12k (20) 12l (22)
12j (21)
Ampicillin 23 22 15 21 -
Amoxicillin 22 23 18 21 -
Norfloxacin 24 17 17 23 -
Penicillin 25 24 20 19 -
Greseofulvin - - - - 25
B. mega S. aureus P. vulgaris E. coli A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity




@98% inhibi t ion
TABLE NO.12a : DATA OF IN VITRO EVALUATION OF ANTITUBERCULAR  ACTIVITY
TAACF, Southern Research Institute Dr. A. R. Parikh
Primary Assay Summary Report Saurashtra University
Sample Corp Where,R= Supplier Assay MTb MIC % comment
ID ID Strain µg/ml Inhib
162234 KB-26 C6H5- Sau.uni Alamar H37Rv >6.25 84
162235 KB-27 4-Br-C6H4- Sau.uni Alamar H37Rv >6.25 -  ''
162236 KB-28 4-Cl-C6H4- Sau.uni Alamar H37Rv >6.25 70  ''
162237 KB-29 4-CH3-C6H4- Sau.uni Alamar H37Rv >6.25 51  ''
162238 KB-30 4-OCH3-C6H4- Sau.uni Alamar H37Rv >6.25 52  ''
162239 KB-31 2-OH-C6H4- Sau.uni Alamar H37Rv >6.25 67  ''
162240 KB-32 4-OH-C6H4- Sau.uni Alamar H37Rv >6.25 11  ''
162241 KB-33 4-NH2-C6H4- Sau.uni Alamar H37Rv >6.25 35  ''
162242 KB-34 3-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 40  ''
162243 KB-35 4-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 9  ''
162244 KB-36 2-C4H3O- Sau.uni Alamar H37Rv >6.25 43  ''
162245 KB-37 2-C4H3S- Sau.uni Alamar H37Rv >6.25 37  ''
NIAID/ Southern Research institute/ GWL Hansen's Center/














A zometh ine  der iva t ives  have been found to  be  potent  drug in
pharmaceutical industries and possess a wide spectrum of biological activity.
Azomethines are also known as Schift base and they are well known interemediate
for the preparation of azetidinone, thiazolidinone, formazone, arylacetamide and
many other derivatives. These are the compounds contain characteristic -C=N-
group.
Holla, B. S. et al.584 have documented azomethine (I) having triazole moiety
and possess good antibacterial activity.
Azomethines are obtained mainly by warming the aldehyde & aromatic
amine togethar. Howeve, it is more convenient to work in a solvent such as alcohol,
dilute acetic acid or glacial acetic acid. Some time the reaction is aided by trace
of acid in other cases the hydrochloride of the amines can be used in the synthesis.
In general Schiff bases do not react further with either of the reagents used in
their preparation as do most of the other types of simple intermediates.
SYNTHETIC ASPECT :
1. General account of the summary of reaction of aldehydes with amine















2. Strache586 and Van Alphen587 have prepared imine involves in two steps.
a. Addition of the amine to the carbonyl group of the aldehyde gives
aldol. The aldol is rerely capable of isolation.
R-CHO+R'-NH2 R-CHOCHNHR'
b. The loss of water to give an imine (azomethine), this corresponds to
the "crotonaldehyde stage" of the aldol condensation.
R-CHOCHNHR' R-CH=N-R'+H2O
3. Oddo & Tognacchini588 have introduced the comparative rates of  formation
of Schiff base from aniline & substituted aniline & aromatic aldehyde using
a cryscopic method follow the course of reaction.
Smalders, et al.589 synthesized some new azomethine like benzylidenena
phthylamine reacts with H p (O) (OCH2CH2Cl)2 to give potential antitumor
reagent phosphonates. Yadawe M. S. and Patil S. A.590 have synthesized
azomethine derivative of type shown as bellow.
Mehta R. H. and et al.591 have synthesized coummarin schiff's base
derivatives of type (II) and examined for their antibacterial activity. Khalafallah
A. K. and Hassan M. E.592 have prepared some styryl Schiff's bases spiro
derivatives as potential antibacterial and antifungal activity. Sharaf El-Din, and
Nabaweyal593 have synthesized some azomethine derivatives (III) having good
antibacterial activity.
185Azomethines...
R  = Ph, 4-Br-C6H4, 4-O2N-C6H4,
2-Cl-C6H4CONH








Chohan et al.594 have synthesized azomethines, which have been screened
and compared for their antibacterial action against bacterial species Escherichia
coli, Pesudomonus aeruginoase and Klebisella pneumoniase.
Das Joydip & Singh, Anilk595 have synthesized azomethine shown as
bellow.
All-trans-N-refinylidene-n-butylamine (IV) can be stabillized in liposomes
of phophatidylcholine. The rate of formation of the Schiff's base is found to
decrease with increasing cholesteral concentration in the membrane.
Deshmukh M. D. and Doshi A. G.596 prepared some new Schiff's bases
show good antimicrobial activity against test organism S. aureus, E. coli, Saigella
dysenteridse and salmonella typhi.
Wang, Yangang; Ye, Wenta; Yang, Jun; Lou, Aihony597 have synthesized
azomethines having good plant hormone activity. Das Arima et al.598 have
prepared Schiff's bases of aminohydroxy guanidine (SB-AHG5) were tested for
antiviral activity against herper simplex virus type I  (HSV-1) and adenovirus type-
5 (Ad-5) alone with 11 other heterocyclic SB-AHG5 some compounds has good
antiadenoviral activity.
Solankee Anjani; Mistry, Pankaj; Patel V. M.599 have synthesized some new








Ram, Tilak et al.600 have synthesized some Schiff's bases, thiazolidinones
4-triazolines, and formazones of 2-chloro phenothiazines and screened against
carrageenin-induced edema in albino rats. The thiazolidinones showed promising
antiinflammatory activity.
Ali, yousif et al.601 have synthesized some Schiff's base derivatives of
glucose contg. acetylenic bond were also prepared Hydroxybenzaldehydes were
first converted to o-prop-2-ynyl-benzaldehydes followed by their condensation
with glucosamine. The prepared Schiff base were tested for their bactericidal
activity against E. coli and staphylococcus aureus.
Cascaval Alexandru; et al.602 have synthesized azomethines, which have
good analgesic and antipyratic proper ties. Pandeya S. N. et al.603 have
synthesized Schiff bases showed good activity against vibrio cholerae non-o.,
shigella boydii, Enterococcus faecalis and Edwaredsiella torla with mic in the
rang of 10-25 µg/ml. Some compounds were found to be active against
salmonellalyphi and vibro cholerae-0, (mic 25-150 µg/ml).
Omar and et al.604 have determined cyclocondensation of azomethines
having good antischistosomal activity.
Pawar R. P. et al.605 have synthesized azomethines by the condensation of
iodovanillin with different substituted aromatic amines. The good antibacterial
activity was determined.
Chohan and co-workers606 have synthesized a novel class of acetyl
ferrocene derived Schiff bases possess antimicrobial activity.
Ergenc and co-workers607 have synthesised azomethine derivatives having
antifungal activity.
187Azomethines...
Holla B. S. et al.608 have prepared mannich bases. Pandey, Taruna et al.609
prepared azomethines and their boron complexes and screened for their antifungal
and antibacterial properties. It is evident that azomethines alone were quite toxic
but their activity increased after complexation.
Yadav Bodke & S. S. Sangapure610 have synthesised some azomethines
and tested for their biological activity. B. Shivarama Holla et al.611 have prepared
some new Schiff's bases having anticancer activity. Ravindra V. Chambhare et
al.612 have prepared some azomethines of type and tested for their antimicrobial
activity. B. Shivarama Holla., et al.613 have synthesized azomethines of type (V)
having antibacterial and anti-inflammatory activity.
Looking to the interesting properties of azomethines, we have synthesised
some new azomethines, which have been described as under.
SECTION-I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
N-ARYL-2-CHLORO-6-METHOXY-QUINOLIN-3-YL-
AZOMETHINES



















SYNTHESIS AND THERAPEUTIC EVALUATION OF N-ARYL-2-
CHLORO-6-METHOXY-QUINOLIN-3-YL-AZOMETHINES
The growing patent literature of recent years demonstrates that the
azomethine derivatives are used as better therapeutic agents. In view of these
findings, it appeared of interest to synthesise Schiff's base of the type (XIII) by
the condensation of 2-chloro-6-methoxy-3-quinolin-carboxaldehyde with various
aromatic amines in order to study their biodynamic behavior.
The constitution of the synthesised products have been characterized by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. In mass spectrometry
m/z value indicate the molecular weight, i.e. when R=4-methylphenyl, molecular
weight=310.5 m/z=311 (m).
The products have been screened for their in vitro antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40 µg/ml. The biological
activities of the synthesised compounds were compared with standard drugs,















IR SPECTRAL STUDY OF N,m-TOLY-2-CHLORO-6-METHOXY-QUINOLIN-3-YL-
AZOMETHINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2914 2975-2950 614
-CH3 C – H str.(sym.) 2860 2880-2860 "
C – H i.p. (def.) 1448 1470-1435 "
C-H o.o.p. (def.) 1377 1395-1370 "
Aromatic C – H str. 3020 3090-3020 615
C = C str. 1571 1585-1570 "
1494 1520-1480 "
C – H i.p. (def.) 1124 1125-1090 "
1053 1070-1000 "
C–H o.o.p. (def.) 823 835-810 "
Quinoline C = N str. 1606 1612-1593 614
nucleus C – Cl. str. 763 800-700 "
Ether C–O–C str. (asym.) 1234 1260-1220 616
C–O–C str. (sym.) 1016 1075-1020 "






PMR SPECTRAL STUDY OF N-p-ANISYL-2-CHLORO-6-METHOXY-QUINOLIN-3-YL-
AZOMETHINE
Internal Standard : TMS; Solvent :CDCl3: Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 3.85 3H singlet Ar-OCH3 -
2. 3.92 3H singlet Ar-OCH3 -
3. 6.95-6.98 2H doublet Ar-H g,g Jgh=8.7
4. 7.14-7.15 1H doublet Ar-Hf Jfe=3
5. 7.31-7.34 2H doublet Ar-H h,h' Jhg=8.7
6. 7.38-7.42 1H d,doublet Ar-He -
7. 7.89-7.92 1H doublet Ar-Hd Jde=9.3
8. 8.88 1H singlet -CHA -






























































































SYNTHESIS AND THERAPEUTIC EVALUATION OF N-ARYL-2-
CHLORO-6-METHOXY QUINOLIN-3-YL-AZOMETHINES
[A] Preparation of N-Acetyl-p-anisidine
See, Part-VIII, Section-I (A).
[B] Preparation of 2-Chloro-6-methoxy-3-quinolin-carboxaldehyde
See, Part-VIII, Section-I (B).
[C] Preparation of N-p-Anisyl-2-chloro-6-methoxy quinolin-3-yl-
azomethine
A mixture of 2-Chloro-6-methoxy-3-quinolincarboxaldehyde (2.20gm,
0.01M) and p-anisidine (1.23gm, 0.01M) was refluxed in ethanol (95%) for 6
hrs. gl CH3COOH is used as catalyst. The contents were cooled and product
isolated was crystallised from ethanol. Yield, 82% (2.67 gm), m.p. 148oC,
(C18H15O2N2Cl; Found : C, 66.12%; H, 4.59%; N, 8.53 %; Required :
C, 66.16%; H, 4.63%; N, 8.57%).
TLC solvent system : Acetone : Benzene (2:8).
Similarly other azomethines were prepared. The physical constants are
recorded in Table No. 13.
[D] Antimicrobial activity of N-Aryl-2-chloro-6-methoxy-quinolin-3-yl-
azomethines
Antimicrobial testing was carried out as described in Part-I, Section-I (D).






















13a C6H5- C17H13ON2Cl 296.6 96 0.43 68 9.44 9.41
13b 2-Cl-C6H4- C17H12ON2Cl2 331 125 0.58 65 8.46 8.43
13c 3-Cl-C6H4- C17H12ON2Cl2 331 152 0.55 63 8.46 8.42
13d 4-Cl-C6H4- C17H12ON2Cl2 331 155 0.56 63 8.46 8.45
13e 4-CH3-C6H4- C18H15ON2Cl 310.5 120 0.53 69 9.01 9.04
13f 3-CH3-C6H4- C18H15ON2Cl 310.5 131 0.50 68 9.01 9.06
13g 4-CH3-C6H4- C18H15ON2Cl 310.5 174 0.61 65 9.01 9.00
13h 2-NO2-C6H4- C17H12O3N3Cl 341.5 164 0.57 64 12.30 12.34
13i 3-NO2-C6H4- C17H12O3N3Cl 341.5 188 0.50 83 12.30 12.28
13j 4-NO2-C6H4- C17H12O3N3Cl 341.5 236 0.53 81 12.30 12.27
13k 3-Cl,4-F-CH3- C17H11ON2Cl2F 349 130 0.48 73 8.02 8.00
13l 4-OCH3-C6H4- C18H15O2N2Cl 326.5 148 0.47 82 8.57 8.53
13m 4-F-C6H4 C17H12ON2FCl 314.5 182 0.51 68 8.90 8.87
































B.mega 18 12 15 22 17 22 16 20 14 13 18 20 18 23 22 24
S.aureus 15 12 18 20 17 18 19 22 15 21 16 17 14 22 23 17
P.vulgaris 12 15 16 20 17 18 19 15 17 12 14 16 15 15 18 17
E.coli 16 15 12 14 18 20 13 15 21 14 21 16 12 21 21 23
A.niger 15 14 17 19 20 18 15 13 14 16 18 14 22 0 0 0







COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[B]
PART-IX
Section - I : Antimicrobial activity of N-Aryl-2-chloro-6-mehtoxy-quinolin-3-yl-azomethines
13f (22) 13d (20) 13d (20) 13f (20) 13e (20)
13h (20) 13h (22) 13g (19) 13i (21) 13m (22)
13l (20) 13j (21) 13k (21)
Ampicillin 23 22 15 21 -
Amoxicillin 22 23 18 21 -
Norfloxacin 24 17 17 23 -
Penicillin 25 24 20 19 -
Greseofulvin - - - - 25
B. mega S. aureus P. vulgaris E. coli A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
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SECTION - II
SYNTHESIS AND THERAPEUTIC EVALUATION OF-2-CHLORO-6-
METHOXY-3-ARYLAMINOMETHYL QUINOLINES
Aminomethyl derivatives of heterocyclic compounds are associated with
diverse biological activity. These finding prompted us to synthesise some
representative aminomethyl derivative of type (XIV) bearing quinoline moiety
obtained by selective reduction of (imine group) of Schiff's bases of type (XIII)
with sodium borohydride in controlled experimental condition as shown in the
reaction scheme.
The constitution of the synthesised products have been characterised by
using elemental  analyses,  infrared spectroscopy, 1H nuclear magnetic
resonance spectroscopy and mass spectrometry. In mass spectrometry m/z value
indicates the molecular weight i.e., when R=3-Cl,4-F-C6H4, moleculor
weight=351, m/z=351.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/
ml. The biological activities of the synthesised compounds were compared with
the standard drugs, recorded on Page No.206. The details of activity have been















IR SPECTRAL STUDY OF 2-CHLORO-6-METHOXY-3-p -NITROPHENYL-
AMINOMETHYL QUINOLINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2999 2975-2950 614
-CH3 C – H str.(sym.) 2831 2880-2860 "C – H i.p. (def.) 1467 1470-1435 "
C-H o.o.p. (def.) 1382 1395-1370 "
Alkane C – H str. (asym.) 2912 2936-2916 "
–CH2- C – H def. 1496 1485-1445 "
Aromatic C–H str. 3062 3090-3020 615
C = C str. 1593 1598-1570 "
1514 1520-1480 "
C–H i.p. (def.) 1122 1125-1090 "
1053 1070-1000 "
C–H o.o.p. (def.) 817 835-810 "
Quinoline C = N str. 1620 1612-1593 614
nucleus C – Cl str. 788 800-700 "
Ether C–O–C str. (asym.) 1232 1260-1220 616
C–O–C str. (sym.) 1035 1075-1020 "







PMR SPECTRAL STUDY OF 2-CHLORO-6-METHOXY-3-p-FLOUROPHENYL
AMINOMETHYL QUINOLINE
Internal Standard : TMS; Solvent : CDCl3: Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 3.87 3H singlet Ar-OCH3 -
2. 4.50 2H singlet -CH2(A1 & A2) -
3. 6.53-6.56 2H doublet Ar-H g,g' Jgh=8.7
4. 6.85-6.88 2H doublet Ar-H h,h' Jhg=8.7
5. 6.98-6.99 1H doublet Ar-Hf Jfe=2.7
6. 7.31-7.35 1H doublet Ar-He -
7. 7.88-7.91 1H doublet Ar-Hd Jde=10.8











































































































SYNTHESIS AND THERAPEUTIC EVALUATION OF-2-CHLORO-6-
METHOXY-3-p-FLOUROPHENYLAMINOMETHYL-QUINOLINE
[A] Preparation of 2-Chloro-6-methoxy-3-quinolincarboxaldehyde
See, Part-VIII, Section-I (B).
[B] Preparation of N-Aryl-2-chloro-6-methoxy quinolin-3-yl-azomethine
See, Part-IX, Section-I (C).
[C] Preparation of 2-Chloro-6-mthoxy-3-p-flourophenylaminomethyl-
quinoline
Sodium borohydride (0.15m, 0.57gm) was added to a methanolic solution
of -N-Flouro-2-chloro-6-methoxy-quinolin-3-yl azomethine (0.01M, 3.14 gm) over
a period of 30 minutes at temperature 5-10oC. The reaction mixture then kept
over night at room temp. The excess borohydride was neutralized by adding water
and the product was extracted with ether. The ether extract was washed with water
untill neutral, then dried over anhydrous Na2SO4 and finally the ether was
evaportated to give aminomethyl derivatives. Yield, 56% (1.77gm), m.p. 128oC.
(C17H14FN2OCl; Found : C, 64.44%; H, 4.41%; N, 8.82%; Required : C,
64.46%; H, 4.45%; N, 8.84%).
TLC solvent system : Acetone : Benzene (1:9).
Similarly other Schiff's bases of type (XIII) were reduced. The physical
constants are recorded in the Table No. 14.
[D] Antimicrobial activity of 2-Chloro-6-methoxy-6-arylaminomethyl-
quinolines
Antimicrobial testing was carried out as described in Part-I, Section-I (D).























14a C6H5- C17H15ON2Cl 298.5 108 0.43 53 9.38 9.34
14b 2-Cl-C6H4- C17H14ON2Cl2 333 87 0.45 61 8.41 8.45
14c 3-Cl-C6H4- C17H14ON2Cl2 333 102 0.58 58 8.41 8.46
14d 4-Cl-C6H4- C17H14ON2Cl2 333 155 0.61 57 8.41 8.37
14e 2-CH3-C6H4- C18H17ON2Cl 312.5 80 0.57 54 8.96 8.91
14f 3-CH3-C6H4- C18H17ON2Cl 312.5 104 0.55 55 8.96 8.91
14g 4-CH3-C6H4- C18H17ON2Cl 312.5 115 0.51 59 8.96 8.93
14h 2-NO2-C6H4- C17H14O3N3Cl 343.5 176 0.52 51 12.22 12.26
14i 3-NO2-C6H4- C17H14O3N3Cl 343.5 123 0.49 63 12.22 12.18
14j 4-NO2-C6H4- C17H14O3N3Cl 343.5 175 0.47 56 12.22 12.19
14k 3-Cl,4-F-C6H3- C17H13ON2Cl2F 351 143 0.52 52 7.47 7.93
14l 4-OCH3-C6H4- C18H17O2N2Cl 328.5 198 0.53 61 8.52 8.53
14m 4-F-C6H4 -C17H14ON2ClF 316.5 128 0.48 56 8.84 8.82
































B.mega 15 16 17 12 14 18 19 15 17 19 20 17 15 23 22 24
S.aureus 21 15 17 12 14 18 17 16 19 21 20 13 12 22 23 17
P.vulgaris 15 12 16 15 19 15 14 17 18 17 16 15 18 15 18 17
E.coli 15 16 17 12 14 19 21 14 16 19 12 14 17 21 21 23
A.niger 21 15 14 13 12 14 18 15 17 16 22 17 14 0 0 0







COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[B]
PART-IX
Section - II : Antimicrobial activity of 2-chloro-6-mehtoxy-3-arylaminomethyl-quinolines
14g (19) 14a (21) 14e (19) 14f (19) 14a (21)
14j (19) 14j (21) 14i (18) 14g (21) 14k (22)
14k (20) 14k (20) 14m (18) 14j (19)
Ampicillin 23 22 15 21 -
Amoxicillin 22 23 18 21 -
Norfloxacin 24 17 17 23 -
Penicillin 25 24 20 19 -
Greseofulvin - - - - 25
B. mega S. aureus P. vulgaris E. coli A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity






See, Part-VI of [A]
SECTION-I : SYNTHESIS AND THERAPEUTIC EVALUATION OF




SYNTHESIS AND THERAPEUTIC EVALUATION OF α-ARYLAMINO-
(2-CHLORO-6-METHOXY-QUINOLIN-3-YL)-ACETONITRILES
Looking to the interesting properties of nitriles, with an intension to
synthesising better therapeutic agents, nitrile derivatives of type (XV) have been
synthesised by the action of 2-chloro-6-methoxy-3-quinolin-carboxaldehyde with
different aromatic amines by using KCN in presence of glacial acetic acid at 0-
5oC, as shown in Reaction scheme (XV).
The constitution of the systhesised products have been characterised by using
elemental analyses, infrared 1H nuclear magnetic resonance spectroscopy and
mass spectrometry. In mass spectrometry m/z value indicates the molecular weight
i.e., R=4-chloro-phenyl, molecular weight=358, m/z=358 (m).
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/
ml. The biological activity of the synthesised compounds have been compared
with the standard drugs, recorded on Page No.216. The details have been cited












R = ArylType (XV)
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IR SPECTRAL STUDY OF α−p-TOLYLAMINO-(2-CHLORO-6-METHOXY-QUINOLIN-3-
YL)-ACETUNITRILE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2912 2975-2950 614
-CH3 C – H str.(sym.) 2860 2880-2860 "
C – H i.p. (def.) 1452 1470-1435 "
C-H o.o.p. (def.) 1365 1395-1370 "
Aromatic C – H str. 3022 3090-3020 615
C = C str. 1596 1585-1570 "
1500 1520-1480 "
C–H i.p. (def.) 1124 1125-1090 "
1056 1070-1000 "
C–H o.o.p. (def.) 810 835-810 "
Quinoline C = N str. 1616 1612-1593 614
nucleus C – Cl. str. 759 800-700 "
Ether C–O–C str. (asym.) 1247 1260-1220 616
C–O–C str. (sym.) 1056 1075-1020 "
Nitrlie C= N str. 2225 2240-2220 618








PMR SPECTRAL STUDY OF α-p-TOLYLAMINO-(2-CHLORO-6-METHOXY-QUINOLIN-
3-YL)-ACETONITRILES
Internal Standard : TMS; Solvent : CDCl3: Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1. 2.28 3H singlet Ar-CH3 -
2. 3.95 3H singlet Ar-OCH3 -
3. 5.75 1H singlet -CHA (Nitrile) -
4. 6.73-6.77 2H doublet Ar-H g,g' Jgh=8.7
5. 7.08-7.10 2H doublet Ar-H h,h' Jhg=8.7
6. 7.24-7.26 1H doublet Ar-Hf Jfe=2.82
7. 7.41-7.46 1H doublet Ar He -
8. 7.91-7.94 1H doublet Ar-Hd Jde=9.3


















































































































SYNTHESIS AND THERAPEUTIC EVALUATION OF α-ARYLAMINO-
(2-CHLORO-6-METHOXY-QUINOLIN-3-YL)-ACETONITRILES
[A] Preparation of N-Acetyl-p-anisidine
See, Part-VIII, Section-I (A)
[B] Preparation of 2-Chloro-6-methoxy-3-quinolin-carboxaldehyde
See, Part-VIII, Section-I (B)
[C] Preparation of α-p-Tolylamino-(2-chloro-6-methoxy-quinolin-3-yl)-
acetonitrile
2-Chloro-6-methoxy-3-carboxaldehyde (2.2gm, 0.01M) dissolved in ethanol
(25 ml) was added to potassium cyanide (0.64gm, 0.01M) dissolved in water (5
ml) followed by glacial acetic acid (5 ml). The contents were then stirred for 5
minutes to form cyanohydrin at 0oC. p-Toludine (1.07gm, 0.01M) dissolved in
methanol was added to the reaction mixture, contents were kept at room
temperature for 24 hrs. and poured into ice. The solid product was crystallized
from ethanol. Yield, 64% (2.16 gm), m.p. 178oC. (C19H16ON3Cl ; Found :
C,67.56%; H, 4.77%; N, 12.44%; Required : C, 67.51%; H, 4.72%; N, 12.40%).
TLC solvent system : Acetone : Benzene (2:8).
Similarly other nitriles were prepared. The physical data are recorded in
Table No. 15.
[D] Antimicrobial activity of α-Arylamino-(2-chloro-6-methoxy-
quinolin-3-yl)-acetonitriles
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solution of inhibition of the test solution are























15a C6H5- C18H14N3OCl 323.5 89 0.48 52 12.98 12.94
15b 2-OCH3-C6H4- C19H16O2N3Cl 353.5 165 0.52 63 11.88 11.81
15c 4-OCH3-C6H4- C19H16O2N3Cl 353.5 116 0.50 71 11.88 11.83
15d 2-CH3-C6H4- C19H16ON3Cl 337.5 163 0.55 55 12.44 12.46
15e 3-CH3-C6H4- C19H16ON3Cl 337.5 149 0.61 61 12.44 12.41
15f 4-CH3-C6H4- C19H16ON3Cl 337.5 178 0.48 64 12.44 12.40
15g 2-NO2-C6H4- C19H15O3N4Cl 382.5 93 0.49 58 15.19 15.15
15h 3-NO2-C6H4- C19H15O3N4Cl 382.5 100 0.53 57 15.19 15.23
15i 4-NO2-C6H4- C19H15O3N4Cl 382.5 170 0.51 64 15.19 15.14
15j 2,6-(CH3)2-C6H3- C20H18ON3Cl 351.5 145 0.54 53 11.94 11.42
15k 2-NO2,4-CH3-C6H3- C19H15O3N4Cl 382.5 86 0.53 55 14.64 14.61
15l 4-Cl-C6H4- C18H13ON3Cl2 358 195 0.55 57 11.73 11.59
15m 4-COOH-C6H4 C19H14O3N3Cl 367.5 156 0.62 53 11.43 11.47
































B.mega 21 14 12 15 18 20 17 16 12 14 18 19 13 23 22 24
S.aureus 13 15 19 12 14 21 18 17 15 17 12 16 18 22 23 17
P.vulgaris 14 14 15 19 16 17 15 12 14 13 13 19 16 15 18
E.coli 18 12 20 14 19 17 15 13 15 17 18 14 16 21 21 23
A.niger 14 12 22 16 18 17 15 17 18 12 14 14 13 0 0 0







COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[B]
PART-X
Section - I : Antimicrobial activity of α-Arylamino-(2-chloro-6-methoxy-quinolin-3-yl)-acetonitriles
15a (21) 15c (19) 15d (19) 15c (20) 15c (22)
15f (20) 15f (21) 15l (19) 15e (19) 15e (18)
15i (18)
Ampicillin 23 22 15 21 -
Amoxicillin 22 23 18 21 -
Norfloxacin 24 17 17 23 -
Penicillin 25 24 20 19 -
Greseofulvin - - - - 25
B. mega S. aureus P. vulgaris E. coli A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
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